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Therapeutic Gene Delivery to Human Pancreatic Islets for Treatment of Diabetes
and the Effect of TFO on Liver Fibrosis Induced by Bile Duct Ligation
Abstract
Ex vivo gene transfer can improve the outcome of islet transplantation for treating Type I diabetes. Earlier
we have shown co‑expression of human vascular endothelial growth factor (hVEGF) and human
interleukin‑1 receptor antagonist (hI‑1Ra) after transfection of plasmid DNA encoding these two genes.
Due to poor transfection efficiency of plasmid DNA and the better known islet transduction efficiency of
adenoviral (Adv) vectors, in this study, we constructed Adv‑hVEGF‑hIL‑1Ra by cloning hVEGF and hIL‑1Ra
coding sequences and polyA signal under separate cytomegalovirus (CMV) promoters in Adenoquick
plasmid (Ad 13.1). There was dose and time dependent expression of these genes after transduction of
Adv‑hVEGF‑hIL‑1Ra into human islets. The mRNA expression of hVEGF and hIL‑1Ra was more than 100
times higher than that of the non‑transduced and bicistronic plasmid transfected control islets.
Transduced islets were viable as evidenced by insulin release upon glucose challenge. Co‑expression of
hVEGF and hIL‑1Ra by islets showed decrease in caspase‑3 activity and apoptosis induced by a cocktail
of inflammatory cytokines such as TNF‑α IL‑1βand IFN‑γ. Compared to non‑treated or Adv‑LacZ
transduced islets, transduction of islets with Adv‑hVEGF‑hIL‑1Ra prior to transplantation under the kidney
capsules of diabetic NOD‑SCID mice reduced the blood glucose levels, and increased serum insulin and
c‑peptide levels. Immunohistochemical staining of the islet bearing kidney sections at day 30 after
transplantation was positive for human insulin, hVEGF and von Willebrand factor.
Further, we decided to replace VEGF with hepatocyte growth factor (HGF) as it not only can promote
revascularization of islets but also increases β ‑cell proliferation. It can also protect the islets from
apoptosis. Adv‑hHGF‑hIL‑1Ra showed dose and time dependent expression of these genes after
transduction into human islets and further showed significant decrease in caspase‑3 induced by the
cytokines. Compared to un‑transduced islets, transduction of islets with Adv‑hHGF‑hIL‑1Ra at 1000 MOI
prior to transplantation under the kidney capsules of streptozotocin‑induced‑diabetic NOD‑SCID mice
reduced blood glucose levels, and increased serum insulin and c‑peptide levels.
These results indicate that the bicistronic Adv vector efficiently expresses both growth factor and
antiapoptotic genes, decreases apoptosis and improves the outcome of islet transplantation.
Liver fibrosis is a consequence of chronic liver disorders which lead to accumulation of extra cellular
matrix (ECM). Particularly, there is an increased accumulation of collagen in the fibrotic liver. We have
therefore used a triplex forming oligonucleotide (TFO) against the type α1 (I) collagen and evaluated,
whether it can attenuate liver fibrosis induced by common bile duct ligation (CBDL). There was a
significant decrease in hydroxyproline levels in TFO‑treated groups compared to non‑treated CBDL group.
Masson’s trichrome staining showed weak staining for collagen in TFO‑treated liver tissues and there was
a predominantly high staining in non‑treated CBDL group. There was over expression of α ‑smooth
muscle actin (α ‑SMA), marker for myofibroblasts following CBDL. Western blotting analysis also revealed
an increase in TGF‑β1 expression, which is a potential marker for fibrosis in the CBDL group compared to
TFO‑treated group. These results suggest that TFO can be used to downregulate Type I collagen gene
expression and can alleviate liver fibrosis induced by common bile duct ligation.
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ABSTRACT
Ex vivo gene transfer can improve the outcome of islet transplantation for treating
Type I diabetes. Earlier we have shown co-expression of human vascular endothelial
growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after
transfection of plasmid DNA encoding these two genes. Due to poor transfection
efficiency of plasmid DNA and the better known islet transduction efficiency of
adenoviral (Adv) vectors, in this study, we constructed Adv-hVEGF-hIL-1Ra by cloning
hVEGF and hIL-1Ra coding sequences and polyA signal under separate cytomegalovirus
(CMV) promoters in Adenoquick plasmid (Ad 13.1). There was dose and time dependent
expression of these genes after transduction of Adv-hVEGF-hIL1Ra into human islets.
The mRNA expression of hVEGF and hIL-1Ra was more than 100 times higher than that
of the non-transduced and bicistronic plasmid transfected control islets. Transduced islets
were viable as evidenced by insulin release upon glucose challenge. Co-expression of
hVEGF and hIL-1Ra by islets showed decrease in caspase-3 activity and apoptosis
induced by a cocktail of inflammatory cytokines such as TNF-α, IL-1β and IFN-γ.
Compared to non-treated or Adv-LacZ transduced islets, transduction of islets with AdvhVEGF-hIL-1Ra prior to transplantation under the kidney capsules of diabetic NODSCID mice reduced the blood glucose levels, and increased serum insulin and c-peptide
levels. Immunohistochemical staining of the islet bearing kidney sections at day 30 after
transplantation was positive for human insulin, hVEGF and von Willebrand factor.
Further, we decided to replace VEGF with hepatocyte growth factor (HGF) as it not
only can promote revascularization of islets but also increases β-cell proliferation. It can
also protect the islets from apoptosis. Adv-hHGF-hIL-1Ra showed dose and time
dependent expression of these genes after transduction into human islets and further
showed significant decrease in caspase-3 induced by the cytokines. Compared to untransduced islets, transduction of islets with Adv-hHGF-hIL-1Ra at 1000 MOI prior to
transplantation under the kidney capsules of streptozotocin-induced-diabetic NOD-SCID
mice reduced blood glucose levels, and increased serum insulin and c-peptide levels.
These results indicate that the bicistronic Adv vector efficiently expresses both
growth factor and antiapoptotic genes, decreases apoptosis and improves the outcome of
islet transplantation.
Liver fibrosis is a consequence of chronic liver disorders which lead to accumulation
of extra cellular matrix (ECM). Particularly, there is an increased accumulation of
collagen in the fibrotic liver. We have therefore used a triplex forming oligonucleotide
(TFO) against the type α 1 (I) collagen and evaluated, whether it can attenuate liver
fibrosis induced by common bile duct ligation (CBDL). There was a significant decrease
in hydroxyproline levels in TFO-treated groups compared to non-treated CBDL group.
Masson’s trichrome staining showed weak staining for collagen in TFO-treated liver
tissues and there was a predominantly high staining in non-treated CBDL group. There
was over expression of α-smooth muscle actin (α-SMA), marker for myofibroblasts
following CBDL. Western blotting analysis also revealed an increase in TGF-β1
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expression, which is a potential marker for fibrosis in the CBDL group compared to
TFO-treated group. These results suggest that TFO can be used to downregulate Type I
collagen gene expression and can alleviate liver fibrosis induced by common bile duct
ligation.
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CHAPTER 1. GENE THERAPY AND ISLET TRANSPLANTATION
1.1.

Introduction

Diabetes mellitus is a chronic metabolic disorder affecting millions of individuals and
is purported to increase inexorably in the coming decades. It is usually a consequence of
environmental or genetic factors resulting in elevated blood glucose levels. It is generally
categorized into two types. Type I or juvenile onset diabetes mellitus is more common in
children due to failure of islets to secrete insulin. Type II diabetes mellitus is more
prevalent in adults wherein the amount of insulin produced is not sufficient to control the
blood glucose levels. It can be a result of insulin resistance or decrease in insulin
secretion by the beta cells. There is no proper cure for diabetes. Insulin is the only
treatment for Type I diabetes patients and most existing therapies often fail to provide
adequate control. There is an urgent need for an effective and better alternative for
managing diabetes and ultimately a cure.
In Type I diabetes, there is a near depletion of the beta (β)-cell mass, suggesting the
need for β-cell replacement.1,2 There is also a reduction in the β-cell mass in Type I or II
diabetes or both. To date, the most effective way of regulating glucose levels is by
administration of exogenous insulin. However, several studies have shown that insulin
administration does not decrease the risk of diabetic complications, and hypoglycemia is
a potential drawback of insulin therapy. This problem is more severe in patients with
erratic glucose levels or hypoglycemic unawareness. In this scenario, whole organ
pancreas transplantation seems ideal and it can completely restore the patients to
euglycemia and maintain long term graft survival. However, the major drawbacks with
pancreas transplantation are the complications that occur with the major surgery required
to perform this procedure and the use of immunosuppressants. There are instances where
simultaneous pancreas kidney transplants have been found beneficial leading to longterm survival.3 However, pancreas transplantation does not overcome the diabetic
complications hyperglycemia, hypoglycemia and microvascular and macrovascular
complications, which are a major concern.4 Also, pancreas transplantation requires major
surgery and lifelong immunosuppression.
Since the advent of Edmonton protocol in 2000, pancreatic islet transplantation has
also become a viable alternative for Type I diabetic patients having life threatening
hypoglycemic episodes. There is a decrease in hypoglycemia and sustained function of
islets after successful islet transplantation. However, patients becoming insulin
independent usually lasts for a few years after which they require administration of
insulin. The major concern with islet transplantation is the use of immunosuppressant’s to
counteract the immune responses elicited from both the host and the transplanted islets.
The other major problem is the primary non-function of islets due to hypoxia resulting
from lack of revascularization or immune mediated destruction of transplanted islets.
In 2000, it was reported that seven consecutive subjects with Type I diabetes were
rendered insulin free following islet transplantation and according to recent reports 72%
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of them are insulin independent. The important achievement of this procedure was the
lack of major surgery for transplanting islets and elimination of hypoglycemia which was
an important complication in pancreas transplantation or any other therapy for Type I
diabetes. The other major outcome of this study was that a number of recipients became
insulin dependent following administration of islets from one donor. However, more than
50% of the patients who became insulin independent needed insulin within 2 years. There
was complete graft failure within a few years. This can be attributed largely to continuing
graft assault by autoimmunity as well as toxicity from immunosuppressive drugs.
Islet transplantation can be done at various sites; however the problems associated
with transplantation need to be overcome to prolong the survival and metabolic outcome
of islets. Autologous or auto-transplantation refers to the transplantation of islets isolated
from the same animal; from same species as allogenic or allo-transplantation and from
different species as xenogenic or xenotransplantation.
There are several factors that cause the primary non-function of the islet graft. Islet
primary non-function is the failure of islets to function immediately after transplantation
due to reasons other than graft failure. During isolation and transplantation islets get
subjected to different conditions including mechanical stress that may result in nonfunction of the β-cells. Several studies have shown that islets fail to function after a
period of time following transplantation either in the pancreatic cavity or in the peritoneal
cavity.5,6 There was a significant depletion of islet mass indicating that primary nonfunction is one of the major reasons we need a large number of islets to achieve
euglycemia. Efficient isolation of pure islets, without altering their physical appearance is
vital for successful transplantation. Islets are the endocrine part of the pancreas and they
need to be separated from the exocrine cells while keeping the intra-islet association
intact. The enzyme collagenase is used to disrupt the islet cells interaction with exocrine
cells followed by separation using density gradient centrifugation. The whole process has
been optimized and pure, viable islets are being successfully isolated.
Islets have extensive intra-islet vasculature which gets disrupted during their
isolation. This vasculature is essential for the supply of nutrients and oxygen to the islets.
Since this vasculature gets disrupted during isolation, revascularization is very essential
for the viability and function of islets following transplantation. Islets get revascularized
by secreting pro-angiogenesis molecular mediators like vascular endothelial growth
factor (VEGF) and its receptors. Therefore, ex-vivo gene delivery of VEGF to islets or by
co-encapsulating VEGF protein with islets can promote revascularization in islets.
Type I diabetes is an autoimmune disorder which poses several challenges for islet
transplantation. Diabetes shows the presence of β-cell reactive auto antibodies and Tcells. The specific nature of T-cells is not known and these can elicit an autoimmune
reaction following transplantation resulting in the destruction of β-cells. The host also has
preexisting antibodies and primed immune cells against β-cell surface epitopes and
immune cells that infiltrate in response to non-self antigens resulting in graft destruction.
Apart from this, the host also reacts to non-self proteins from the transplant tissue
resulting in the loss of islet function.
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Usually when a foreign tissue is introduced into the host by transplantation, foreign
antigens are recognized by the host leading to a cascade of events called antigen
presentation. The various peptide fragments, secreted and shed proteins come in contact
with the host immune cells forming a major histocompatibility complex (MHC).7 MHC
can be either class I or II and usually autoimmunity occurs when there is matching for
MHC class II.8 Class II molecules are only expressed in certain immune cells including
macrophages and dendritic cells known as antigen presenting cells (APCs). APCs can be
either from the host or from the donor. The antigens present on MHC II molecules on the
donor APCs acts as foreign antigens to the transplant recipient when the lymphocytes
migrate in the host. Donor antigen presentation can be mediated either through direct or
indirect pathways. Direct pathway engages antigen presentation by the donor APCs,
while the indirect pathway engages host APCs. Understanding the pathways involved in
immune destruction of transplanted islets is critical for developing strategies to protect
them.
Various immune suppressive strategies are employed to minimize or block the
immune activation. Immunosuppressive drugs are often employed with transplantation.
However, the risks from these drugs are unknown and they may further inhibit the graft
function. Therefore, there is a need for improvements in immunosupprresion and also
improvement in the quality of islets.
The potential use of genes as therapeutics has attracted great attention for the
treatment of severe and debilitating diseases. Gene therapy is the method of treating
diseases using genes so that the patient’s somatic cells can produce the specific proteins
that are lacking. This will prevent the limitations associated with the administration of
therapeutic proteins. It is an approach to treat diseases, or ultimately prevent a disease by
replacing defective genes, introducing new genes, or changing endogenous expression of
genes. Gene therapy can be used to express genes that can aid in the process of islet
transplantation and improve the overall survival and function of islets. It can aid in
modifying the islets resulting in improved survival and function of islets posttransplantation. Current gene therapy approaches are mainly oriented to improve islet
function, block apoptosis and inhibit primary non-function of islets. The various gene
vectors that are being used for islet transplantation include adenoviral, adeno-associated
virus, herplex simplex virus vectors, retro and lentiviral vectors and non-viral vectors.
The main problem associated with viral vectors is immunogenicity and safety concerns.
Anti-apoptotic, angiogenic genes are most commonly expressed using these vectors to
improve the metabolic function and survival of islets following transplantation.
Gene therapy uses viral or non-viral vectors to deliver genes to synthesize specific
therapeutic proteins. Viral vectors are derived from retroviruses, lentiviruses,
adenoviruses, adeno-associated viruses, herpes viruses and pox viruses.9 The
development of vectors for cell-specific gene expression is the major goal of any gene
therapeutic strategies. Significant progress has been made in the construction of gene
expression vectors that combine different functions required for efficient gene transfer.10
Gene medicine usually contains an expression system that controls the transcription
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of a gene within the target cell and a specific delivery system that controls the
biodistribution of these vectors to specific locations in the body. Cationic liposomes,
peptides and polymers are commonly used as transfection reagents for gene expression
plasmids, while viral vectors usually do not require any of these transfection reagents.
Viral vectors have shown much promise in the field of gene therapy, but there are
safety issues, they may also be limited in terms of their DNA loading capacities.10
Immune activation by viral vectors is a major concern as many of the vectors with high
therapeutic activity in vitro fail to do so in vivo.11 Moreover, increasing their yield can be
quite difficult. To minimize their immunogenicity, the surface of the viral vectors is often
modified by conjugating to polyethylene glycol (PEG).12
Gene expression plasmids offer many advantages over viral vectors, including large
packaging capacity, no integration into the host genome, and lower toxicity. However,
their level of gene expression is often lower and shorter than that of the viral vectors.
Recent advances in gene expression systems have shown great improvement in the
transfection levels of non-viral vectors. Plasmid vectors can also be used to silence a
gene, thereby causing the inhibition of an abnormal protein production in the body.13
Plasmids have also shown to play a role in the formation of viral vectors, e.g., two
plasmid rescue systems used to construct an adenoviral vector. The various parts of the
gene expression system are outlined here.
1.2.

Gene Expression Systems

Gene expression systems are broadly classified into plasmid and viral vectors.
Basically, these vectors have the machinery in them to facilitate the production of target
proteins in the host upon transfection or transduction.
1.2.1.

Basic Components of Plasmid Vectors

A gene expression plasmid contains a complementary DNA (cDNA) sequence coding
for either a full gene or minigene, and several other genetic elements including promoter,
introns, polyadenylation (polyA) sequences, and transcript stabilizers to control the
transcription, translation, and protein stability and/or secretion from the host cell.14
The transcription unit comprises of 5’ enhancer/promoter upstream of the gene
encoding a therapeutic protein and polyA signal downstream of the gene. An intron is
also assembled into either 5’ or 3’ untranslated region (UTR), leading to elevation of
mRNA levels. Plasmid vectors can be designed to express two genes simultaneously
driven by different promoters or a single promoter or by insertion of an internal ribosome
entry site (IRES). IRES was first discovered in picornaviruses, Encephalomyocarditis
Virus (ECMV) and poliovirus.15,16 They have the ability to translate two open reading
frames from a single mRNA transcript. Usually the IRES is inserted between two
transgenes to be expressed. IRES confers unequal expression of genes and usually the
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expression of the downstream gene is relatively higher than the upstream gene and this
may confirm the internal ribosome entry.16 However, recent studies have shown that this
may not be always true. Production of low level of monocistronic RNAs putatively due to
splicing of the bicistronic transcript due to the presence of 3’ splice site (SS) which can
show increased expression of the downstream gene.17 This warrants a careful RNA
structural analysis to confirm the functionality of the IRES.
We have constructed a bicistronic plasmid vector (phVEGF-hIL-1Ra) encoding
human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor
antagonist (hIL-1Ra) driven by cytomegalovirus (CMV) and elongation factor-1α (EF1α) promoters, respectively, in pBudCE4.1 vector.18 There was dose and time dependent
expression of hVEGF and hIL-1Ra genes when they were transfected into human islets.
However, the expression levels of these two genes were not sufficient to decrease blood
glucose levels of diabetic mice following transplantation with phVEGF-hIL-1Ra
transfected islets. Not only the expression, but the extent of expression of genes was also
low for this bicistronic plasmid.
1.2.1.1. Bacterial Elements
Plasmids encode two features that are important for their propagation in bacteria. One
is the bacterial origin of replication (Ori), which is a specific DNA sequence that binds to
factors that regulate replication of plasmid and in turn control the number of copies of
plasmid per bacterium. The second required element is a selectable marker, usually a
gene that confers resistance to an antibiotic. The marker helps in the selection of bacteria
that have the gene expression plasmid of interest. Escherichia coli (E.coli) are commonly
used bacteria for propagating plasmids. It has the property to transfer DNA either by
bacterial conjugation, transduction or transformation. The extensive knowledge about
E.coli’s physiology and genetics accounts for its preferential use as a host for gene
expression. Human insulin was the first product to be produced using recombinant DNA
technology from E.coli.
1.2.1.2. Transcription Regulatory Elements (TRE)
Gene expressing plasmids contain transcription regulatory elements (TRE) to control
transcription. The Jacob and Monad theory postulates that a repressor protein may bind to
the operator region downstream of a promoter preventing RNA polymerase from binding
to the host DNA.19 This operator region may overlap with the promoter for the operon
being controlled. However, if this repressor is controlled, it may increase gene
expression.20 Transcription regulatory elements play a significant role in gene expression
and may also impart specificity. The important sequences in the gene that control
transcription are the cis-acting sequences that are situated in the immediate vicinity of the
gene and they together constitute the functional unit or domain.21
Heterologous TREs can be included in the adenoviral genome to allow replication
only in the cells in which TREs are functional, resulting in cell specificity.22 Addition of
new TREs in an expression vector can alter the transcription of the target gene. These
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new elements can mimic the action of the genomic TREs of the target genes resulting in
an alteration in transcription. These elements can be added to either increase or decrease
transcription depending on the requirement. In diseases like cancer, the expression of
target genes can be altered by this method.23 For example, homeodomain-containing
transcription factor pancreatic duodenal homeobox-1 (Pdx-1) plays a key role in
maintaining the function of pancreas and is also known to have a prominent role in beta
cell development.24 When this Pdx-1 was introduced into an adenoviral vector and
expressed in hepatocytes, they were transformed into pancreatic endocrine hormone
producing cells.25 Modulating the expression vector with TREs can be done to increase
the gene expression. Embryonic stem cells have the potential to transform into insulin–
producing cells that can be transplanted for treating Type I diabetes.26 TREs can play a
major role in transformation of these cells.
1.2.1.3. Enhancer
Enhancer is a short region of DNA that can bind trans-acting factors, much like a set
of transcription factors, to enhance transcription levels of genes in a gene-cluster. Usually
in the bound proteins facilitate promoter-binding proteins to interact with the promoter.27
An enhancer does not need to be particularly close to the genes it acts on, and need not be
located on the same chromosome. An enhancer does not need to bind close to the
transcription initiation site to affect its transcription, as some have been found to bind
several hundred thousand base pairs upstream or downstream of the start site.28
Enhancers can also be found within introns. An enhancer's orientation may even be
reversed without affecting its function. Furthermore, an enhancer may be excised and
inserted elsewhere in the chromosome, and still affect gene transcription.29 That is the
reason why intron polymorphisms are important, even though they are not transcribed
and translated. Enhancer-promoter interaction also plays a major role in immune reaction
following in vivo administration of plasmid vectors. Epo enhancer when inserted into the
plasmid expressing VEGF showed expression of VEGF in hypoxia conditions, whereas
the plasmid without epo enhancer showed no expression of VEGF.30
1.2.1.4. Promoter
Promoter is a DNA sequence that enables a gene to be transcribed. The promoter is
recognized by RNA polymerase, which binds it and then initiates transcription.
Promoters regulate protein synthesis indirectly by having an active role in demarcating
genes to be used for mRNA synthesis. The promoter region is usually the beginning of an
operon, which is a collection of neighboring genes, and controls the region transcribed
into the same mRNA molecule.31 Therefore, DNA transcription begins after RNA
polymerase has bound downstream of the therapeutic gene. This effect is seen as DNA
unwinding into single strands. Therefore, any mutation in this region will prevent RNA
polymerase from binding. Transcription begins at the first base of the target gene+1
position is the TATAA sequence or TATA box, 5’ TATA (A/T) A (A/T)-3’. This region
ensures that transcription starts at the proper point and binds the RNA polymerase II
complex.32 Another transcription start site is the CCAAT box (consensus sequences 5’GGTC-CAATCT-3’) located upstream of the TATA box.
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Promoter sequences play an important role not only in initializing gene transcription,
but also in immunostimulation.33 The promoter type governs the strength and duration of
transgene expression. Viral promoter elements are first known to be used in an expression
vector to express proteins for gene therapy. Cytomegalovirus (CMV), Rous sarcoma
virus (RSV) and Simian virus 40 (SV40) are some of the strongest known viral
promoters. However, there are some drawbacks with the use of viral promoters such as,
lack of specificity and immunostimulation that results in inactivation. For example, CMV
promoter shows expression in most cell types, however, its activity decreases over a
period of 3-4 weeks.34 This is possibly due to the inhibition by cytokines, methylation, or
inactivation by repressor proteins. This is also true for other viral promoters like SV 40
and RSV.35 Because of these reasons there is an urgent need to develop promoters based
on non-viral cellular regulatory elements.
Sustained gene expression is quite difficult to achieve. However, some promoters
have been reported to confer sustained gene expression from plasmid DNA in vivo. These
promoters include β-actin, elongation factor 1-α, (EF1-α), or ubiquitin. The activity of
these promoters is usually lower than that of viral promoters, but can be increased by
addition of viral or cellular enhancer components.36 CMV early enhancer/chicken β actin
(CAG) is a promoter of this kind. It consists of CMV enhancer and first intron of chicken
(or human skeletal) β-actin. It shows activity similar to or more than the CMV
promoter.37,38 It shows a greater activity in viral vectors, but its expression profile needs
to be established for using in plasmid vectors.35
EF1-α promoter has been reported to confer sustained gene expression compared to
CMV promoter, but its expression is 10-fold lower than the CMV promoter.39 Promoters
from three of the known human ubiquitin genes, UBA, UBC, UBB have been
incorporated in plasmid vectors. Luciferase gene expression was measurable upto 6
months when the plasmid contained UBC promoter.39 This clearly suggests that if proper
promoters are incorporated into the gene expression system, it is possible to attain
sustained gene expression. Primary bone marrow-derived mesenchymal stromal cells
(BMMSC) were inserted with glucose-responsive promoter-regulated insulin transgene.
HBMMSC glucose-responsive promoter, EGR1 was identified from these cells which
showed rapid glucose-induced transgene secretions simulating normal human islets.40
1.2.1.5. Untranslated Region (UTR)
The 5’ untranslated region (5’-UTR) is the region of the mRNA transcript that is
located between the capsite and the initiation codon. The linkage between methylated G
residue and 5’ to 5’ triphosphate bridge is known as the cap structure, which is essential
for efficient initiation of protein synthesis. The 5’-UTR is known to influence mRNA
translation efficiency. In eukaryotic cells, initiation factors first interact with the 5’ cap
structure and prepare the mRNA by unwinding its secondary structure. An efficient 5’UTR is usually moderate in length, devoid of secondary structure and upstream initiation
codons. It has AUG with an optimal context. Any of the following features that influence
the accessibility of the 5’ cap structure to initiation factors will influence mRNA
translatability.41,42
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Initiation codon AUG appears to be the best recognized when it is in the context of
the sequence CCRCCAUGG with purine (R) at -3 and/or guanine (G) at+4 (A of AUG is
numbered+1). If an AUG occurs alone or in conjunction with a short open reading frame
located between the cap site and the genuine AUG, translation will be inhibited.
Secondary structures of the UTRs inhibit translation. 5’ UTR lengths that are greater than
32, but less than 100 nucleotides, permit efficient recognition of the first AUG. Most
naturally occurring 5’ UTRs are 50-100 nucleotides in length.
The 3’ UTR comprises the mRNA sequence following the termination codon. It plays
an important role in mRNA stability.31 AU rich motifs are commonly found in the 3’
UTR of mRNA of cytokines, growth factors, and oncogenes. These are mRNA instability
elements and should be removed for maximal gene expression. This is achieved when
standard 3’ UTR sequence is used in the place of one found in cDNA. Another way is to
minimize the length of the 3’ UTR by placing the hexanucleotide of the poly A signal
immediately downstream of the stop codon.43
1.2.1.6. Polyadenylation (polyA) Signal
The efficiency of polyadenylation (polyA) is important for gene expression, as
transcripts that failed to be cleaved and polyadenylated are rapidly degraded in the
nuclear compartment.44 PolyA signal is a recognition site consisting of AAUAAA
hexamer positioned 10-30 nucleotides upstream of the 5’ end and a GU or U rich element
located maximally 30 nucleotides downstream of the 3’ end.31 PolyA signal is needed for
the formation of the 3’ end of most eukaryotic mRNA. It directs two RNA processing
reactions: site specific endonucleolytic cleavage of the RNA transcript, and stepwise
addition of adenylates to newly generated 3’ end to form the polyA tail.
1.2.1.7. Intron
The protein coding region in the gene is often interrupted by stretches of noncoding
DNA called intron. Transcripts from intronless genes are rapidly degraded in the nuclear
compartment, leading to lower gene expression.45 Therefore, for maximal gene
expression in eukaryotic cells, at least one intron should be included within the
transcription unit. Introns also promote mRNA export from the nucleus. The addition of
intron A or B to the plasmid encoding ICAM-2 promoter and subsequent expression in
HUVEC or PsCAM cells increased the expression of the transgene.37 Introns thus can
affect gene expression and if used in a proper way can enhance the expression of
transgenes.
1.2.1.8. Stop Signal
Stop signal is the DNA sequence at which RNA polymerase II is halted and detached
from the DNA, thereby a stop or nonsense codon stops translation. However, polyA
occurs at 5’ AAUAAA 3’ sequence in the mRNA. The polyA polymerase cleaves after
the U residue and adds 50-250 adenylate residues. Stop signal not only plays an
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important role in gene regulation at the translational level allowing for rapid changes in
specific protein levels, but also provides an opportunity to alter codon specificity.
1.2.1.9. Multiple Cloning Sites (MCS)
A multiple cloning site (MCS), also known as polylinker, is a short segment of DNA,
which contains many restriction sites. Restriction sites within an MCS are unique and
occur only once within a particular plasmid. MCS are commonly used for cloning of a
single or multiple cDNAs due to its unique restriction endonuclease recognition sites
identified with ease. The recombinant plasmid can be altered in such a way that the
desired gene can be inserted into the plasmid and expressed. If there is no particular
restriction site for a particular transgene, the restriction site can also be inserted into the
MCS and then can be used to clone the gene in that vector.
1.2.1.10. Fusion Tags
Fusion tags are inserted in expression systems so that the DNA location and site
specificity can be known. A variety of protein tags have been used to allow recombinant
fusion protein to be detected and purified without the use of an antibody or other protein
specific assays. Short epitope tags and fluorescent protein tags are commonly used for
gene function studies. Epitope tags such as His/C-term, xpress, V5, FLAG, HA, and cMyc, circumvent the requirement for specific antibodies against target proteins.
Fluorescent protein tags, such as green fluorescent protein (GFP) provides information on
the cellular location of the fusion proteins. Since addition of the any amino acid residues
may alter the properties of the target proteins, special consideration should be given on
the intended use of the protein and on minimizing the adverse effects when picking a tag.
Typically, a specific protease cleavage site is introduced in the tag and the target protein
to facilitate tag removal if desired. Fusion tags can be incorporated into the plasmid
vectors to enhance protein expression and solubility of the expressed protein.46 Fusion
tags can be classified into two types based on their application: Affinity tags and
solubility enhancing tags. Affinity tags help in purification of recombinant protein,
whereas the solubility-enhancing tags can be used to improve the solubility of proteins.
Usually the solubility enhancing tags are either large peptides or proteins. Fusion tags
like glutathione S-transferase (GST) and maltose binding protein (MBP) show both
affinity and solubility enhancing properties.47,48 Recombinant proteins often show large
variability in their expression, solubility, stability, and function, making them difficult
targets for large-scale analyses and production. Fusion tags can be very effective in
improving the expression, solubility, and production of biologically active proteins,
especially for proteins whose expression is very difficult.
1.2.2.

Persistence of Gene Expression

Regulation of gene expression and having a sustained expression is the key for many
diseases. Plasmid based systems usually confer transient gene expression, with less than
20% of the peak level at day 3.49 This warrants the need for expression of transgene over
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a period of time. This is especially important in diseases like cancer where the cells
divide continuously. An ideal non-viral vector should be able to provide persistent
expression of the transgenes without affecting the host cells. Persistent gene expression
can be achieved either by prevention of promoter attenuation, use of replicating plasmid,
modulation of immune response, attachment of matrix/scaffold regions or optimizing
plasmid size.
1.2.2.1. Prevention of Promoter Attenuation
The major drawback of non-viral vectors is the lack of sustained gene expression.
Transient gene expression in vivo is partly due to promoter shutdown.35 This is especially
true for viral promoters, such as CMV and SV 40 promoters. Methylation of plasmid
DNA is involved in promoter inactivation, which can be prevented by removing the
methylation sites (CpG motifs) from the plasmid construct. Transient gene expression is
also due to the destruction of the transfected cells by the immune system.50 Viral
promoters are sensitive to cytokines, which may explain the decline of their activity in
vivo.35 Promoter inactivation has also been attributed to specific tissue types. For
examples, smooth muscle gamma actin (SMGA) and flk-1 promoters show their activity
specifically in smooth muscles and endothelium, respectively.10
1.2.2.2. Use of Replicating Plasmids
Extrachromosomally replicating vectors have great potential for use in gene therapy
due to their high transfection levels and sustained expression of transgenes. The use of
replicating plasmids results in sustained gene expression without the integration of gene
into the host genome. This also reduces the risk of insertational mutagenesis. Replication
elements usually from viral DNA are inserted into the expression systems that enable the
plasmid to replicate extra chromosomally. This can be done by the introduction of a
mammalian origin of replication51 sequence into plasmid. The best characterized oris in
mammalian cells are from viral sources, such as SV40, human papo virus (BKV), bovine
papilloma virus (BPV), and the Epstein Barr virus (EBV).52 Modeling the bacterial power
and efficiency of self-replication would greatly increase therapeutic protein expression.
Since the plasmids do not integrate into the host genome, they reside outside as
episomes. They have several advantages over integrating systems: (1) the transgene is not
interrupted or subjected to regulatory constraints that often occur from integration into
cellular DNA, (2) higher transfection efficiency, (3) episomes show a low mutation rate
and tend not to rearrange, and (4) they have the ability to transfer large amounts of
DNA.10
Plasmids can replicate in both prokaryotic and eukaryotic cells provided they have
certain elements which allow them to do that, e.g., EBV viral elements.53,54 Several viral
constructs including EBV, BK virus (BKV), SV 40 and bovine papilloma virus have been
used in constructing replicating plasmid vectors. Trans-acting factors are needed for the
formation of episomal vectors, but there is a risk of transformation following their use.
This is especially seen in the case of polyomaviruses (BKV, SV40) which contains a T-
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antigen (Tag) as a trans-acting factor. Tag purportedly binds to tumor suppressor gene
p53 causing chromosmal aberrations and alters the gene expression.55 Considering this,
EBV viral elements are safer as they have a low mutation frequency and can easily
incorporate large amounts of DNA.55 EBV nuclear antigen 1 (EBNA1) and oriP
constitute the EBV viral elements which impart stability to the viral DNA in the host
cells.53,55 EBNA1 dimer/oriP complex controls the replication and transcription of
plasmid vector. EBNA facilitates binding of the plasmid vector to the nuclear matrix.
EBV–based vectors showed higher expression of transgenes compared to conventional
vectors when they were studied in vivo. However, EBV based vectors are associated with
certain drawbacks including integration into the host genome and oncogenicity.55
Ehrhardt et al., replaced the CMV promoter with a cellular promoter to minimize the
silencing effects attributed to nonmammalian sequences.56 However, if the problems
associated with the use of viral elements can be solved, they can be far superior compared
to the conventional vectors.
1.2.2.3. Modulation of Immune Response
One of the major drawbacks of gene therapy is the interaction of the gene expression
vectors with the host immune system. Although non-viral vectors produce less immune
response compared to viral vectors, their effect should not be overlooked. CpG motifs are
unmethylated with an ability to stimulate B cell proliferation, macrophage activation and
maturation of dendritic cells. The bacterial and viral DNA contains a large amount of
unmethylated CpG motifs. Plasmid vectors usually contain bacterial or viral elements
with large number of CpG motifs, which lead to acute inflammatory response commonly
seen in non-viral vectors. The sequence GTCGTT is the most active stimulatory CpG
motif in humans leading to the activation of immune pathways. Following activation of
the immune system by CpG motifs, gene expression is decreased due to cytokine
mediated promoter shutdown and apoptosis of expressing cells.
When constructing plasmid vectors the immunostimulation of the CpG motifs can be
reduced by methylation of the CpG motifs, using neutralizing CpG motifs or by
elimination of CpG motifs. Plasmid vectors containing significantly less amount of CpG
motifs showed very less immunostimulation compared to the ones with more CpG
motifs.57 The presence of a single unmethylated CpG has been shown to elicit an
inflammatory response when delivered to lung. However, CpG free vectors showed no
inflammatory response and increased the duration of transgene expression in the lung.39
Li et al., have shown that intradermal injection of plasmid DNA encoding glutamic acid
decarboxylase (GAD) polypeptide synthesized in both pancreatic islet and skin tissue and
pro-apoptotic protein BAX, ameliorated new-onset Type I diabetes in NOD mice and
increased skin allograft survival in a BALB/c-C57BL/6 model system in a donor-specific
manner by preventing the autoimmune response that elicited following skin
transplantation.58 Plasmid gene expression has resulted in expression of T-cells
previously, whose effect can be negated by administering the plasmid DNA encoding this
peptide.
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1.2.2.4. Matrix/Scaffold Attachment Regions (MARs)
Matrix/scaffold attachment regions (MARs) govern the architecture of the nucleus by
establishing protein boundaries. Several proteins bind to MARs and these proteins are
known as MAR binding proteins. MAR binding proteins are very significant as they
regulate transcription, replication, repair and combination.59 Incorporation of matrix
attachment regions in the plasmid construct may be thus helpful in maintaining episomal
plasmid for extended periods. The potentially immunostimulatory and transforming
properties of viral protein used in episomes and other components of the expression
system impede the application of these systems for gene therapy. Alternatively MARS
can be incorporated into circular plasmids to replace transacting viral gene products.
MARs have been characterized as AT rich sequences generally composed of 4-6 bp
motifs such as ATTA, ATTTA, or ATTTTA.60 These sequences are commonly used with
gene enhancers and the ori. Incorporation of these sequences has been used to enhance
the transcriptional activity of integrated transgenes.60
MARs are often situated in proximity to promoters, replication origins and other
important regions in the genome. MARs have been known to play a role in several
biological activities due to their affinity to the nuclear matrix. They have been known to
play a role in initiation of transcription, promote long term expression of the transcript by
counteracting the effects of DNA methylation, protect transgenes from negative effects of
the genomic surroundings and promote histone acetylation, act as an enhancer and
promote replication.61 MARs have been incorporated in episomally replicating plasmids
to impart stability to the vector and increase the longevity of transgene expression. MARs
are used to replace the viral elements from these vectors to minimize the
immunostimulatory effects from them. An episomal vector was developed by replacing
the Tag protein with MAR from human β-interferon gene while retaining the SV40 ori
sequence. This vector replicated episomally in CHO cells and showed stable expression
for more than 100 divisions. Argyros et al.,62 demonstrated persistent transgene
expression in the liver after hydrodynamic injection of the plasmid containing MARs
driven by human liver specific promoter α1-anti-trypsin (AAT). MARs protected the
AAT promoter by inhibiting methylation of CpG motifs, resulting in sustained expression
of luciferase,62 while the plasmid containing MARs and CMV promoter did not show
persistent luciferase expression. This signifies that even though MARs imparts extrachromosomal stability, duration of gene expression also depends on the choice of
promoter used.
1.2.2.5. Plasmid Size
Plasmid stability is dependent on its size. Most gene therapy studies use plasmids of
less than 10kb. To prolong gene expression, bacterial artificial chromosomes (BAC) have
been used in non-dividing cultures.63 A BAC-plasmid vector encoding 185kb DNA insert
of human beta globin gene and EBV orip and EBNA-1 transactivator showed persistent
gene expression indicating the usefulness of plasmid size.64 A episomal BAC vector
encoding entire genomic human low-density lipoprotein receptor (LDLR) and LacZ
showed high transfection and persistent gene expression of LDLR and LacZ.65
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Bacterial components in the plasmid vector are known to elicit immunostimulation.
Therefore, several research groups are investigating the possible use of minicircle
plasmids, which do not have bacterial origin of replication or antibiotic resistance marker.
These are generated in E.coli by site-specific recombination. Following injection of
minicircle plasmid encoding VEGF165 into Balb/c mouse heart and skeletal muscle,
VEGF165 gene expression levels were similar or higher to that observed with
conventional plasmid vectors encoding VEGF165.66 In another study, minicircle mediated
delivery of interferon-γ (IFN-γ) was more efficient in inducing antiproliferative and antitumor effects in human nasopharyngeal cancer cell lines than conventional vectors due to
its sustained expression of IFN-γ levels.67 This suggests that minicircle plasmids may be
a viable alternative to conventional plasmids vectors.
1.2.3.

Site-Specific Gene Expression

Targeting of gene medicines to specific cells is often required to prevent toxicity to
healthy cells and to decrease the required dose. Differential gene expression among cell
types is possible because different genes are driven by different sets of promoters and
enhancer sequences, and each of these regulatory binding sequences contain binding sites
for multiple transcription factors. Changing the set of transcription factors will lead to the
activation of a different set of genes, leading to a change in the cell’s protein expression
profile. Selective expression of transgenes in specific cells or tissues can be achieved by
constructing DNA expression cassettes that contain gene regulatory regions that are
recognized by transcription factors, specially present in or selectively expressed by the
target cell population. This targeting is based on tissue specificity where transcription is
directed specifically among healthy tissues or tumor specific by using elements which are
active in tumor cells due to aberrant gene expression or tumor biology.
There are various well characterized regulatory elements controlling cell type specific
expression, with target tissues including pancreas, breasts, bone, brain, kidney, bladder,
lung, and liver. Tissue specific promoters display a natural activity in normal tissues
without discriminating diseased cells from healthy ones. Therefore, for toxic protein
expression the use of tissue specific promoters is limited to dispensable tissues such as
melanocytes, prostate, breasts, endocrine, and exocrine tissues.12,68,69 Combining tissue
specific promoters with additional targeting moieties can further increase their utility. For
example, combination of tumor and tissue specific promoters may enable targeting
specific cells/malignancies within nondispensable tissues. Cellular regulatory elements
often have low activity, which can be addressed by inclusion of a strong promoter
element from viral or cellular origin. For example, Pujal and colleagues have shown the
specificity of the keratin 7 promoter which is expressed in pancreatic ductal cells
predominantly than acinar cells which depends on the krt 7-234 bp sequence. This
sequence is included in a plasmid or viral vector exhibits the same specificity as krt7
promoter and may help in targeting pancreatic ductal adenocarcinoma cells in vitro and in
vivo.70 Targeting expression to a particular organ, tissue and cells greatly reduces the
antibody response to a foreign protein and results in sustained expression.71
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Most composite promoters contain one or two enhancer elements fused to a
heterologous promoter sequence. This concept has been used to create promoters with
combinations of regulatory sequences. Li et al., randomly assembled muscle-specific
elements from four different muscle-specific promoters and then screened these novel
promoters for activity.72 One sequence showed 8-times the activity of natural muscle
promoters. However, this was done in vitro. It is more challenging to develop a promoter
with greater expression in vivo.
1.2.4.

Pulsatile Gene Expression

Gene switches are introduced into expression systems to make use of circadian
rhythm by extraneously administering compounds to control the production of
therapeutic proteins by turning on or off the transcription of an administered gene. Gene
switches are incorporated into the vector for gene regulation. This feedback control may
prevent overexpression and possible deleterious protein production. In this system the
target gene is inactive until the administration of an exogenous compound or ligand.73,74
Progesterone antagonists, tetracycline, ecdysone and rapamycin are used as inducing
agents to turn on gene regulation of the expression vector.
1.3.

Viral Vectors

Recombinant viruses are unique in being naturally evolved vehicles that efficiently
transfer their genes into host cells. Viral vectors are composed of either a RNA or DNA
core, or process different genomic structure and host ranges. However, they often have
risks such as toxicity, immunogenicity, and/or potential for viral recombination. Novel
developments of viral vectors mainly aim at reduction of immunogenicity and improved
vector production. Several kinds of viruses including retrovirus, adenovirus (Adv),
adeno-associated virus (AAV), herpes simplex virus (HSV), have been manipulated for
gene transfer and are commonly used for modifying islet cells to improve their survival
and enhance their metabolic activity. These viral vectors have their own unique
advantages and disadvantages as discussed below.
1.3.1.

Retroviral Vectors

Retroviruses are enveloped single stranded RNA viruses. Retroviruses have a genome
of about 7-10kb, composed of gag, pol, and env genes flanked by elements called long
terminal repeats (LTRs). These are essential for integration into the host genome and
signify the beginning and end of the viral genome. The LTRs control the expression of
viral genes, and hence act as enhancer- promoter. The final element of the genome, the
packaging signal (ψ), helps in differentiating the viral RNA from the host RNA.75 Gag
proteins are major components of the viral capsid. Pol proteins are involved in the
synthesis of viral DNA and integration into the host DNA, whereas env proteins play a
role in association and entry of viral particles into the host cell.

14

The viral genome can be manipulated and viral genes can be replaced by inserting
transgenes. The transgenes can be controlled by the LTRs or alternate enhancer-promoter
sequences can be engineered within the transgene. The chimeric genome is then
introduced into packaging cell lines, which produce all the viral genes but these have
been separated from the LTRs and the packaging sequence. So, the chimeric viral
genomes are assembled to produce the retroviral vector. The culture medium containing
the packaging cells which produce the retroviral vector is used directly to infect target
cells for gene transfer.
Retroviral vectors have several advantages including stable transduction of dividing
cells, less immunogenic and persistent transgene expression. However, there are several
disadvantages of these vectors. These include random insertion into the host genome,
limited DNA insertion capacity (8kb), low titers, and inactivation by complement
systems, and inability to transduce non-dividing cells.
LIM-homeobox transcription factor islet-1 (Lsl1) is a transcription factor derived
from heart during embryogenesis that has the ability to self-replicate was delivered to the
endothelial cells and mesenchymal stem cells (MSCs) using a retroviral vector resulting
in promotion of angiogenic and vasculogenic properties. Lsl1 expressing endothelial cells
also promoted vascularization in vivo in C57BL/6J mice.76
1.3.2.

Lentiviral Vectors

Although lentiviral vectors belong to the retroviral family, they have the ability to
infect both dividing and non-dividing cells.77 Human immunodeficiency virus (HIV) is
the best known lentivirus.78 HIV lentiviral vector is very efficient as it has the ability to
infect and express genes in human helper T cells and macrophages. Apart from the genes
gag, pol and env, the HIV has six accessory proteins tat, rev, vpr, vpu, nef, and vif. These
proteins regulate the synthesis and processing of viral RNA and other replicative
functions. The accessory proteins can also be removed without affecting the production
efficiency of the virus. The env gene from HIV-based vectors allows the infection of cells
which express protein CD4+, so in these vectors this is substituted with other env gene
from other RNA viruses which have a broader infection spectrum.
The significance of lentiviral vectors lies in the fact that they can efficiently transduce
non-dividing cells or terminally differentiated cells such as neurons, macrophages,
hematopoietic stem cells, muscle and liver cells and other cell types for which gene
therapy methods could not be used. These vectors, when injected into the rodent brain,
liver, muscle, or pancreatic islet cells, show a sustained gene expression for over six
months.79 These vectors do not show any immune response and no potent antibody
response and thus can be ideal for in vivo gene delivery.
Magnetic nanoparticles have been used for the delivery of lentiviral vectors to
endothelial cells. This method provides the direct targeting of the lentiviral vectors to
endothelial cells even in perfused blood vessels apart from increasing the transduction
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efficiency.80 However, one problem with lentiviral vector is random integration into
genomic DNA. This integration although desirable can be problematic as it can cause
differential gene expression in the cells and most importantly insertational mutagenesis
resulting in malignant transformation. To alleviate this effect non-integrating lentiviral
vectors are developed by point mutations into the chromosome binding site, the viral
DNA binding site of the viral integrase.81
There are reports in the literature where they have used lentiviral vectors encoding
immunosuppressive proteins to protect the islets from allogenic rejection.82 They have
showed that genetic engineering of beta-cells using gp19K-and RID alpha/betaexpressing lentiviral vectors can be a viable alternative to eliminate or reduce treatment
with the potent immunosuppressive agents necessary at present for prolonged
engraftment with transplanted islets.
1.3.3.

Adenoviral Vectors

Adenoviruses are non-enveloped double- stranded DNA viruses, and can infect both
dividing and non-dividing cells. Natural adenoviruses cause benign respiratory tract
infection in humans. Their genome contains many genes and they do not integrate into
the host DNA. Replication deficient adenoviruses can be generated by removing the E-1
gene necessary for viral replication and replacing it with the gene of interest (for
example, hepatocyte growth factor) and a promoter sequence.83 These recombinant
viruses are replicated in cells that express the product of the E-1 gene and generated in
high concentrations.84
Cells infected with recombinant adenoviruses can express the therapeutic gene, but
they cannot replicate as the genes needed for replication are absent. These vectors
efficiently transduce cells and gene expression lasts for about 5-10 days. Therefore, Adv
vectors are suitable for transient gene expression unlike retroviral vectors, which show
long term expression. Adv vectors show extended duration of expression when given to
nude mice or with an immunosuppressant indicating that the immune system may be
responsible for the short duration of expression.85
The immune reaction elicits both cell killing ‘cellular response’ and antibody
producing ‘humoral response.’ Cellular response results in the killing of infected cells
with T-lymphocytes, whereas the humoral response results in the production of
antibodies to Adv proteins, resulting in the diminished transgene expression following
subsequent infections.85,86 Moreover, most human beings are likely to have antibodies to
Adv from previous infections as it is a commonly found virus infecting the human
population. To address this problem, second generation of Adv vectors were produced
where the other genes of the Adv genome are deleted like the E-3 gene required for
eliciting immune response. However, their expression was not longer than 20-40 days.87
Gutless Adv vectors are also generated in which all Adv genes are deleted. The viral
DNA contains the start and end of the viral genome along with the viral packaging
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sequence. They showed expression for about 84 days.88 However, the production of these
gutless Adv vectors is somewhat difficult. Furthermore, they still have immunological
problems, which need to be overcome for their in vivo applications. One way of getting
around this problem is to develop strategies to target the viral particles to the required
cells, tissues, or organs. Targeting of vectors can ideally lead to less immunological
responses and fewer amounts of viral particles are needed to get the desired therapeutic
effect. However, Adv vectors transduce cells more efficiently only in the presence of
coxsackievirus and adenovirus receptors (CAR).89,90 Immune response from Adv vectors
can further be attenuated by deleting E4 or a part of the E4 region.
To target Adv vector to a specific cell or tissue usually Adv capsid, such as its fiber,
protein IX (pIX), or hexon is altered. Of these, fiber proteins are the most studied. These
proteins consist of a tail, shaft, and knob.91 The C-terminal knob is responsible for
binding with CAR receptors.78,92 Targeting was achieved by incorporating an RGD
peptide or a stretch of lysine residues (KKKKKKK [K7] peptide), targeting the αV
integrins, or heparin sulfate proteoglycans into the HI loop or C-terminal region of the
fiber knob.93-95 pIX can also be altered to achieve targeted delivery using an Adv vector.96
pIX is a structural protein that sustains the structural integrity of the viral particles.
Kurachi et al., reported the enhanced transduction efficiency of Adv vectors containing
an RGD peptide in the c-terminus of pIX with α-helical spacer.91 Also modification of
hexon containing RGD peptides (DCRGDCF) at HVR 5 region in the Ad vector can
render them infective via αv- integrin receptor without any affinity to the CAR receptor.97
Therefore, modifications in the Adv capsid at pIX or hexon containing heterologous
peptides render them more selective as compared to that at fiber in the capsid.
Biermann et al., have also shown that the modification of high-capacity Adv vectors
by incorporating either 6X-His epitope or RGD peptide into the HI loop of the fiber knob
rendered the vectors more effective and allowed efficient targeting towards different cell
types.98 Targeting can also be achieved by affinity immobilization of Adv particles to the
surfaces of biodegradable nanoparticles resulting in improved transduction through
uncoupling cellular uptake from CAR receptor.99 The Adv nanoparticles containing
inducible nitric oxide synthase (iNOS) inhibited growth of culture smooth muscle cells
more compared to Adv encoding reporter gene GFP without any therapeutic activity
(AdGFP) or Adv without any gene (Ad free vector).
Islets are non-replicating cells which secrete insulin following an increase in blood
glucose levels in the body. When there is death of islets due to genetic or immune
mediated defects, one of the major alternatives is transplantation of islets. However, due
to inadequate vascularization and subsequent immune attacks, islet transplantation did
not achieve the success it was meant to. We have shown that human vascular endothelial
growth factor (hVEGF) expression promotes new blood vessel formation and improves
the outcome of islet transplantation.100 To enhance hVEGF gene expression, we
transduced human islets with bipartite Adv vectors encoding hVEGF and human
interleukin-1 receptor antagonist (hIL-1Ra) to promote revascularizaton and protect the
human islets from apoptosis.101 Bipartite vector results in simplifying the amplification
and purification of Adv vectors but also minimizes the Adv backbone for transduction,
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thereby lessening the immunogenic effects of the vector. There was dose dependent
increase in expression of hVEGF and hIL-1Ra from islets transduced with Adv-hVEGFhIL-1Ra. We confirmed whether the Adv vector is causing any detrimental effects to the
islets by measuring the stimulation index of islets following transduction by Adv vector.
Islets transduced by Adv vectors were as functional as untransduced islets. There was a
decrease in caspase-3 levels in Adv transduced islets compared to untransduced islets
when they were incubated with inflammatory cytokines. The expression was several
times higher than the bicistronic plasmid vector phVEGF-hIL-1Ra. Following
transplantation of Adv-hVEGF-hIL-1Ra transduced islets in non-obese diabetic severe
combined immunodefecient (NOD-SCID) mice, there was a decrease in blood glucose
levels and increase in insulin and c-peptide levels.
Over-expression of hVEGF can be detrimental to islets and surrounding tissues and
can lead to development of tumors.102,103 On the other hand hepatocyte growth factor
(HGF) is a potent mitogen of human islets and is known to promote β-cell proliferation
and is also anti-apoptotic.104 We therefore constructed a bipartite Adv vector encoding
hHGF and hIL-1Ra (Adv-hHGF-hIL-1Ra) driven under a separate CMV promoter.101
The vector showed increase in hHGF and hIL-1Ra genes with increase in multiplicity of
infection (MOI) and duration. It did not affect the function of islets and showed
decreased caspase-3 levels compared to the untransduced islets. Transduction of islets
with Adv-hHGF-hIL-1Ra enhanced the level of Bcl-2 protein and inhibited the levels of
Bax protein demonstrating the protective effect of hHGF and hIL-1Ra co-expression.
There was also decrease in blood glucose levels and increase in insulin and c-peptide
levels in NOD-SCID mice transplanted with Adv-hHGF-hIL-1Ra transduced islets.
Immunohistochemcial staining of islet bearing kidney sections revealed stronger positive
staining for human insulin, hHGF and hvWF suggesting more efficient blood vessel
formation in Adv-hHGF-hIL-1Ra transduced islets. This shows that Adv vectors can be
utilized for efficient and high expression of transgenes with less immunogenic effects
compared to non-viral vectors. However, these vectors can still elicit immune responses
more so in vivo setting. Therefore, by further removing the E4 or part of E4 genome of
the Adv vectors and by selectively targeting the Adv vector to a specific organ or tissue
by attaching a ligand (Gal-PEG) to it can further enhance the prospects of Adv vectors in
gene therapy.
1.3.4.

Adeno-Associated Viral Vector

Adeno-associated virus (AAV) is a simple non-pathogenic single-stranded DNA virus
and is a member of parvoviridae family. AAV is composed of two open reading frames
(ORF), rep and cap, and two inverted terminal repeats (ITRs) that define the start and end
of the viral genome and packaging sequence,105 whereas the cap gene encodes viral
capsid (coat) proteins and rep gene is for replication and integration. AAV requires
additional genes to replicate, which are usually provided by an Adv or a herpes simplex
virus (HSV). The AAV vector is produced by replacing the rep and cap genes with the
transgene. Only one out of 100-1000 viral particles is infectious. Apart from the
production of AAV vector being laborious, these vectors also have the drawback of
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limited packaging capacity for the transgene (4.7kb). Furthermore, there are no packaging
cells which can express all the proteins of the virus. Since rAAVs are deleted of viral
genes, these vectors are less immunogenic. However, specific circulating bodies to
rAAVs have been detected limiting their potential administration.106
AAV vectors are the most promising vectors for gene therapy in improving islet
transplantation outcomes mostly due to their low immunogenicity and high safety
profile.107 AAV vectors are commonly used to deliver immunosuppressive genes to islets
prior to transplantation resulting in improving the longevity and function of transplanted
islets.108 Interleukin-10 (IL-10) gene was delivered to the islets using an AAV vector
encoding IL-10 (AAV-IL-10) protected the islets from autoimmune recurrence and
allogenic rejection.109 AAV-IL-10 mediated delivery of IL-10 mitigated the previously
activated T-cells and protected the islets from immune rejection.
1.3.5.

Other Vectors

HSV, which infects the cells of nervous system, is being developed as a vector. This
virus contains 80 genes, of which one can be replaced to produce the vector.51 The use of
recombinant baculoviruses, containing mammalian regulatory elements for efficient
transient and stable transduction of different mammalian cell types is being explored.110
Alpha viruses are being used in the development of vaccines.111,112
1.4.

Gene Delivery Systems

Gene delivery systems help in controlling the location of a gene within the body by
regulating the biodistribution of a gene expression system. They aid in protecting the
gene expression systems from premature degradation in extracellular milieu and allowing
non-specific or cell-specific targeting of the expression system. Some delivery systems
are designed for specific targeting to a receptor or aid in intracellular trafficking of the
gene expression system. Some of the common gene delivery systems used are discussed
below.
1.4.1.

Liposomes

Plasmids are generally complexed with cationic liposomes to protection them from in
vivo degradation and to enhance intracellular delivery. Cationic lipids are composed of a
hydrophobic lipid anchor group, linker group and a positively charged head group.
Cationic lipids present in the liposome interact electrostatically with negatively charged
phosphate backbone of DNA, thereby condensing the DNA into a more compact
structure. These are most commonly used synthetic carriers for delivery of
oligonucleotides, siRNAs, and plasmid DNA. The degree of transfection by cationic
liposomes mainly depends on the extent of DNA condensation, cellular uptake by
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interaction with biological surfaces and membrane fusion via transient membrane
destabilization for cytoplasmic delivery avoiding lysosomal degradation.
Although pH sensitive liposomes can be used to encapsulate DNA, low entrapment
efficiency and high serum sensitivity limits their usage. This scenario changed with the
introduction of the first cationic lipid 2, 3-dioleyloxypropyl-1-trimethyl ammonium
bromide (DOTMA).113 Most of the research is being done to increase the transfection
efficiency through the modification of the functional headgroups. Also, enhancing the
transgene expression has become the focus of many studies. New cationic lipids were
developed by modifying the headgroups of DOTMA resulting in increased transfection
efficiency.((±)-N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1propanaminium bromide (DMRIE), which was synthesized by modifying DOTMA
showed increase in transfection efficiency and transgene expression. (3β (N-(N’,N’Bimethylaminoethane) carbamoyl) cholesterol (DC–Chol) was the first cholesterol based
cationic lipid.114 Its structure was further modified by conjugating to polyamino groups
resulting in more positive charges.114 Spermine and spermidine were conjugated to
cholesterol to reduce cytotoxicity and increase the delivery of antisense
oligonucloetides.61 Changing spermine or spermidine into a secondary amine showed
better transfection efficiency both in vitro and in vivo.115 Some of the cationic lipids such
as DC-Chol, DMRIE, and GL-67 have been used in early clinical trials, but the results
were not encouraging. Hetreocyclic cationic lipids have also been studied for gene
delivery. Some of these compounds showed better transfection abilities and lower
cytotoxicity compared to cationic lipids with linear primary amines or polyamines as
head groups.114
Pyridinium-based cationic lipids have been shown to have similar or higher
transfection efficiency compared to commercially available cationic lipid formulations.
Pyridinuim lipids displayed higher transduction efficiency in cells which are not easily
transfected by other cationic lipids like Lipofectin, and transfect relatively a large group
of cells.116 Zhu et al., have synthesized a series of pyridinium lipids containing a
heterocyclic ring and a nitrogen atom and prepared liposomes with co-lipid L-α
dioleoylphosphatidylethanolamine (DOPE) and cholesterol (Chol) by sonication.117
Pyridinium lipids with amide linker showed significantly higher transfection efficiency
compared to their ester counterparts. Liposomes prepared at a 1:1 molar ratio of
pyridinium lipid and a colipid showed higher transfection efficiency when either DOPE
or cholesterol was used as a colipid to prepare liposomes. The pyridinium lipids with a
trans-configuration of the double bond in the fatty acid chain showed higher transfection
efficiency than its counterparts with cis-configuration at the same fatty acid chain length.
In the presence of serum, C16:0 and lipofectamine significantly decreased their
transfection efficiencies, which were completely lost at serum concentration of 30% and
higher, while C16:1 trans-isomer still had high transfection efficiency under these
conditions.
The liposomal vector interacts with extracellular components in serum after in vivo
administration. This often causes failure of the liposomal vector to reach the target cells.
To have a targeted liposomal vector system, a ligand is required to bind to the receptor of
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the target cells. Nasopharyngeal epidermal carcinoma cells which express excess of folate
receptors were targeted by liposome-entrapped polycation-condensed DNA (LPDII)
anionic liposome encapsulating polylysine condensed DNA tagged with folate.118
Lys2Gal3, an aminogalactoside was used to target hepatoma in vitro119 which is a cationic
formulation consisting of lipopolymaine, DOPE (helper lipid) and a galactolipid (DPPELys2Gal3). Lipososmal vectors have been used to improve the islet transplantation
process. Hypoxia is one of the major factors resulting in primary non-function of
transplanted islets. VEGF gene was delivered to the islets using a cationic lipid which
increased the transfection efficiency and resulted in better glycemic control of the
transfected islets.120 Tacrolimus was sufficiently encapsulated in liposomes and delivered
to the islets resulting in improved immunosuppressive effect.121 However, toxicity at
higher doses is a major concern.
1.4.2.

Cationic Peptides

Major difficulties in non-viral delivery are the ability of the vectors to condense the
DNA, targeting to specific cells, disrupt the endosomal membrane and deliver it to the
nucleus. Peptide based vectors can be successfully employed to overcome these barriers.
Cationic peptides condense DNA by interacting with its negatively charged phosphate
backbone.
Poly (L-Lysine) (PLL) is one of the first cationic peptides to deliver genes. However,
increase in length of PLL leads to cytotoxicity. It shows very less transfection efficiency
and needs another fusogenic peptide to facilitate plasmid release into the cytoplasm.
Since PLL cannot escape from the endosome without addition of endoosmolytic agents
such as chloroquine, Midoux and Monsingy have constructed a histidine-substituted
polylysine, since histidine protonates at acidic pH in the endosome. Cationic peptides can
be linked to cell specific ligands and bound to plasmids through electrostatic interaction.
These complexes can interact specifically with target cell receptors leading to
internalization of the complex into the cells.
Synthetic peptides which are conjugated to lipids usually show better binding ability
to DNA. For example, inclusion of dialkyl or diacyl chains in the cationic peptides
improves their ability to bind to DNA and reduces aggregation of complexes in ionic
media.9,31,122 Synthetic peptides derived from the N-terminus of influenza virus
haemagglutinin and the rhinovirus VP-1 protein,123 or artificial amphipathic peptides
were used.31 These peptides may have specificity for endosomal pH due to acidic
residues (glutamic and aspartic acids) aligning on one side of an amphipathic helix. At
neutral pH, the negatively charged carboxylic groups destabilize the alpha-helical
structure resulting in the multimerization of peptides and/or membrane interaction. The
pH specificity can be enhanced by introducing additional glutamic acids into the peptide
sequence.124 The enhancement of gene expression is strongly dependent on the peptide
sequence. The activity of cationic lipid/DNA complexes has been enhanced by mixing
with Sendai virus envelopes. This approach and related systems utilizing neutral lipids
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and liposome-like reconstituted envelopes (virosomes) based on Sendai virus or influenza
viruses have been found effective for gene delivery.125
Amphipathic cationic peptides such as, gramicidin S, is incorporated into a DOPE
lipid/DNA composition to facilitate gene delivery. Incorporation of gramicidin S and
DNA into asialofetuin-labeled liposomes was used for receptor-mediated gene delivery
into primary hepatocytes.126 The influence of influenza virus-based peptides on cationic
lipid-based transfection was studied.127 Wagner et al., showed that the use of positively
charged lipospermine/DNA complexes resulted in 3 to 30-fold enhancement in gene
expression by association with the peptides.128 Kamata et al., also showed that influenzaderived peptides can increase the level of gene expression of a lipofectin formulation by
up to five-fold.129 Thus, escape from endocytic vesicles does not seem to be a major
barrier for optimized, positively charged DNA/lipospermine or lipofectin complexes.
However, for less positively charged lipospermine complexes gene transfer efficiency
was found to be increased by a factor of 50 to 1000 by synthetic peptides INF6 (influenza
virus derived sequence) and INF10 (artificial sequence).128 Wilke et al., generated novel
DNA complexes containing a palmitoyl-modified DNA-binding peptide showing
enhanced transfection activity. Gene transfer was found to be restricted to mitotic cells.130
Membrane-modifying peptides are able to enhance both lipofection and polyfection.
Transfection efficiency of cationic peptide-based systems are strongly dependent on the
presence of endosomolytic peptides or related agents (like glycerol, viral particles) which
enhance cytoplasmic delivery.123 Transfection efficiencies can be improved up to more
than 1000-fold by endosomolytic compounds.128
It is important to determine (i) whether membrane-modulating peptides and DNA
carriers can influence other intracellular steps beside endosomal escape or cell membrane
fusion, such as the transport of the DNA into the nucleus of the cell; and (ii) whether the
results obtained with membrane-active peptides in cell culture can also be exploited for in
vivo gene transfer.125 Cationic peptides can be used for modifying the surface of islets to
prevent inflammation mediated loss of islet function following islet transplantation.
Teramura et al., modified the surface of islets was modified with a poly (ethylene
glycol)-phospholipid conjugate bearing a biotin group (biotin-PEG-lipids, PEG
MW:5000).131 This resulted in improved islet function as surface modification mitigated
the blood mediated inflammation.
1.4.3.

Cationic Polymers and Lipopolymers

Polyethyleneimine (PEI), polypropylenimine, and polyamidoamine dendrimers have
been employed for gene delivery. PEI117 is a branched cationic polymer widely used in
the gene delivery. It condenses the plasmids into colloidal particles that effectively
transfect genes into a variety of cells in vitro.132 PEI contains several secondary amines
which get protonated in the acidic environment of the endosome. This leads to endosomal
swelling and subsequent membrane disruption leading to the release of the vector into the
cytosol. However, high molecular weight PEI (>25 kDa) show cytotoxicity and
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PEI/plasmid vector complexes under aggregation on storage, resulting in less gene
expression. Chemical modification of low molecular weight PEIs may improve
transfection and reduce cytotoxicity.
Mahato and associates synthesized a water soluble lipopolymer by conjugating
cholesteryl chloroformate to branched PEI of 1800 Da through primary and secondary
amines.133 This polymer was non-toxic to CT-26 colon carcinoma cells and did not cause
any aggregation compared to PEI/DNA complexes. Cholesterol will promote both
micellar formation and hydrophobic interaction with plasmid and cellular membrane
while PEI will condense DNA via electrostatic interaction. However, transfection of
islets with lipofectamine showed less transfection efficiency as islets are approximately a
cluster of 1000 non-dividing cells an new strategies are needed for improving the
transfection efficiency.134
1.4.4.

Hybrid Vectors

Both viral and non-viral vectors have their own advantages and disadvantages. There
is much work going in developing new ways of better utilizing these vectors for gene
expression and delivery. One such approach is to overcome the limitations of individual
vectors by combining them. These vectors are called hybrid vectors. For example, the
adenovirus hexon protein enhances the nuclear translocation and increases the transgene
expression of PEI/pDNA complexes.135 PEG has been widely used for conjugating with
adenoviral vector to prolong its circulation half-life, enhance transgene expression and
prevent immune activation.136
Cationic lipids and polymers may help in improving the transduction efficiencies of
viral vectors. These are particularly useful in cells which do not have the specific viral
receptors. The cationic nature of these molecules may promote binding to the negatively
charged viral capsid altering the cell surface and allow internalization of viral particles.
This can also elicit very less immunostimulation. For example, cationic liposomes
promote delivery of Adv vectors into target cells which lack the CAR receptors and αvintegrin receptors improving transgene expression.137 Diamond and his colleagues have
showed that delivery of Adv vectors associated with dexamethasone-spermine (DS)
conjugate to the lung enhanced targeting to the conducting airway epithelium and
reduced immune response.138 Further, formulation of Adv encoding LacZ with DS/DOPE
allowed re-administration of the adv vector, with little loss of transgene expression.
Adv vector can also be coated with polymers bearing side chains containing
positively charged quaternary amines and carbonyl thiazolidine-2 thione groups to
prevent binding of Adv vector to plasma protein and consequently prolong blood
circulation half-life and more deposition of the vector at diseased sites.139
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1.4.5.

Receptor-Mediated Gene Transfer

Targeting ligands have been incorporated into DNA complexes for site or cell
specific gene delivery.125 By attaching the DNA to a domain that can bind a cell surface
receptor, such as the asialoglycoprotein receptor, transferrin receptor, the efficient
cellular process of receptor-mediated endocytosis, can be utilized. Conjugates with
polylysine, protamines, histones, PEI, cationic lipids, and other polycations have been
generated and tested for receptor-mediated endocytosis. Hong and his colleagues used a
hydroxycamptothecin (HCPT) loaded polyethylene glycol (PEG) niosomes attached with
transferrin to the terminal group of PEG. This system showed high antitumor activity
compared to non-transferrin bound niosomes.117 To enhance the uptake and specificity,
Wu and Wu generated a polylysine-based, asialoglycoprotein receptor-specific gene
delivery system by incorporation of asialoorosomucoid–polylysine conjugates into DNA
complexes.140,141 Complexes could be efficiently delivered into endosomes or other
internal vesicles of cells, but they were still separated from the cytoplasm by a
membrane. This accumulation of complexes in internal vesicles strongly reduced the
efficiency of gene transfer. Receptor-mediated delivery into a hepatocyte cell line
resulted in uptake of DNA into practically all cells, but only a few cells expressed the
delivered gene.142
1.5.

Concluding Remarks

Although significant progress has been made to employ gene therapy in the clinic to
treat various severe and debilitating diseases, there is still no FDA approved products in
the market. This can be attributed to the lack of proper gene expression and delivery
systems. While viral vectors efficiently transduce cells and have shown promise in their
clinical trials, there are still some safety concerns, especially immunostimulation and
integration within the host. Although non-viral vectors are relatively safe, transgene
levels are very low and transient and thus many vectors have failed to perform well in the
clinical trials. Therefore, efforts are being made to generate hybrid systems by combining
the beneficial effects of non-viral and viral vectors. This has led to the significant
enhancement in the gene expression, with minimal toxicity and immunogenicity. Further,
the use of cellular promoters offers targeting of the vector to specific target tissues
rendering the vector safe and efficacious. There is a definite need to develop targeting
strategies for non-viral vectors which can compensate for the inefficient gene transfer.
Islet transplantation usually results in decrease of hypoglycemic episodes which is a
major drawback for conventional insulin therapy. Gene therapy has resulted in mitigating
the hypoglycemic episodes and improved the graft function and showed higher levels of
insulin and c-peptide levels in the majority of patients. However, this can last only for a
few years after which patients have to resort to insulin therapy. Gene therapy can be
implemented in this case to prevent the toxic effects of immunosuppressive agents and
control the inflammation and immune reactions following islet transplantation. With
recent improvements in gene delivery and increased understanding of the mechanisms
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underlying graft failure, gene therapy for islet transplantation has the potential to move
closer to the clinic as a treatment for patients with Type I diabetes.
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CHAPTER 2. BIPARTITE VECTOR ENCODING hVEGF AND hIL-1Ra FOR EX
VIVO TRANSDUCTION INTO HUMAN ISLETS
2.1.

Introduction

Type I diabetes is an autoimmune disease that results in the destruction of insulin
producing -cells of the pancreatic islets. Significant progress has been made in the field
of islet transplantation where islets are transplanted via the portal veins of Type I diabetic
patients. However, a large number of islet grafts do not secrete insulin, as they fail to
revascularize upon transplantation and undergo apoptotic cell death.143
Islets have an intricate microvasculature, which is disrupted during the isolation and
purification process. Revascularization to the transplanted islets is known to improve the
delivery of nutrients and oxygen to the inner core of islets leading to their
survival.100,133,144,145 Transduction of islets with an adenoviral (Adv) vector encoding
hVEGF or hepatocyte growth factor has been shown to promote the formation of new
blood vessels, leading to improved islet survival.100,133,145,146 Apart from
revascularization, islet grafts also need to be protected from apoptosis induced by
inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha
(TNF-α) and interferon-γ (IFN-γ) released from resident macrophages and infiltrating
immune cells at the transplantation site.147 Immunosuppressive medications are used
simultaneously to protect transplanted islets, but reports of severe side effects induced by
immunosuppressive drugs have prompted attention on developing ways to reduce their
toxicities.148 Among various cytokines, IL-1β plays a key role in apoptotic cell death.
Inhibition of IL-1β receptor binding using interleukin-1receptor antagonist (IL-1Ra)
resulted in improved islet survival and function.149-151
Considering the favorable uses of hIL-1Ra and hVEGF, we recently constructed a
plasmid vector encoding these two genes (phVEGFhIL-1Ra) by cloning hIL-1Ra under
the cytomegalovirus (CMV) promoter and hVEGF under the elongation factor-1R(EF1R) promoter in pBudCE4.1 vector, and demonstrated dose and time dependent
expression of hVEGF and hIL-1Ra at after transfection.18 Since transfection efficiency of
this bipartite plasmid into human islets was very low and the better known transduction
efficiency of Adv vectors, in this study, we constructed a bipartite Adv vector encoding
hVEGF and hIL-1Ra driven by separate CMV promoters. The use of bipartite vector
encoding these genes not only simplifies the amplification and purification process of
Adv vectors but also decreases the use of total Adv backbone for transduction, which is
expected to minimize immunogenic and toxic effect of Adv vectors. We determined
transduction efficiency, islet function and caspase-3 release upon incubation with
inflammatory cytokine cocktail of TNF-α, IL-1β and IFN-γ. We then transplanted islets
under the kidney capsules of NOD-SCID mice after transduction with Adv-hVEGF-hIL1Ra and determined the blood glucose, insulin and c-peptide levels. Finally, the islet
bearing kidney sections of these diabetic mice were stained for human insulin, hVEGF
and von Willebrand factor (hvWF).
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2.2.

Materials and Methods

2.2.1.

Materials

Agarose, tris-borate-EDTA buffer, goat serum, glucose and haematoxylin solution
were purchased from Sigma-Aldrich Co. (St. Louis, MO). Fetal bovine serum (FBS) and
CMRL-1066 media were purchased from MediaTech Cellgros (Herndon, VA). Human
VEGF and IL-1Ra ELISA kits and cytokines IL-1β, TNF-α, and IFN-γ were purchased
from R&D Systems (Minneapolis, MN). Human Insulin ELISA kits were purchased from
Alpco Diagnostics (Windham, NH), and RNA extraction and Caspase-Glo 3/7 assay kits
from Promega (Madison, WI). SYBR Green real time PCR master mix and reverse
transcription reagents were purchases from Applied Biosystems (Foster City, CA).
2.2.2.

Methods

The methods used in this study are described below.
2.2.3.

Construction of Adv-hVEGF-hIL-1Ra

A bipartite Adv vector encoding hVEGF and hIL-Ra genes was constructed with the
help of OD 260, Inc. (Boise, ID). Briefly, hIL-1Ra cDNA along with rabbit β-globin
polyA was cloned into pE3.1 shuttle plasmid, while hVEGF fragment along with rabbit
β-globin polyA was inserted into pE1.2 shuttle plasmid. The pE3.1-hIL-1Ra plasmid was
further modified by removing the intron adjoining CMV promoter. These plasmids were
transformed in super competent TOP 10 cells and amplified in terrific broth media.
pE1.2-hVEGF and pE3.1-hIL-1Ra were digested to excise these expression cassettes for
ligation with SfiI digested AdenoQuick 13.1 plasmid simultaneously using T4 DNA
ligase overnight at 16ºC. The ligated products were packaged into phage lambda particles
using MaxPlax packaging extract (Epicentre, Madison, WI). The packaging mixture was
used to infect E.coli XL-1Blue (Stratagene, La Jolla, CA) and clones were selected on LB
supplemented with 25µg/ml kanamycin and 50µg/ml ampicillin. The Pac I linearized
cosmid was transfected into 293 cells to rescue the virus. Three viral plaques were
amplified, and their genomic DNAs were extracted. The presence of hVEGF and hIL1Ra expression cassettes was confirmed by restriction analysis with Hind III and Not I.
The clone containing the two genes was transduced to 293 cells, and the viral extract was
further transduced into 293 cells, amplified and purified on two CsCl gradients. The
bands harvested were dialyzed against GTS buffer (25% glycerol, 25mM NaCl, 20mM
Tris-HCl, pH 8) and viral suspension was collected, filtered and stored at -70ºC. Once the
construction was confirmed for the insertion of genes hVEGF and hIL-1Ra, the virus was
tested for expression of these genes in vitro and then in vivo.
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2.2.4.

Determination of Viral Titer

The following methods were used to calculate the viral titer.
 OD 260-SDS Method: Adv-hVEGF-hIL-1Ra was purified using CsCl density
gradient. The purified virus was diluted at different concentrations in the
range of 0.1-1.0 in 0.1% sodium dodecyl sulfate (SDS) buffer. The
absorbance was recorded at 260nm. The viral titer was calculated based on the
extinction coefficient of 1.1X1012 virus particles (VP) per Abs260 unit in the
presence of SDS buffer.
 Plaque Assay: Freshly confluent 6cm dishes seeded with 293 cells were
infected with various dilutions of Adv-hVEGF-hIL-Ra. Three days later, the
cells were split into 10cm dishes to boost virus plaque formation. The cells
were split again into 15cm dishes 10 days later. The formation of virus
plaques was monitored up to 3 weeks after which the infection titer was
calculated.
 Infectious Viral Titers: The infectious viral titer was also determined by using
an Adeno-X rapid titer kit from Clontech. Different dilutions of Adv-hVEGFhIL-1Ra was taken and transduced to AD-293 cells, using untransduced cells
as a control. After 48h post-transduction, AD-293 cells were fixed and
incubated with Anti-hexon antibody, followed by a secondary horse radish
peroxidase (HRP)-conjugated antibody. Then the cells were stained with 3, 3’
diaminobenzidine tetrahydrochloride (DAB) substrate and positively stained
cells were counted under a microscope, and the titer was determined.
2.2.5.

Islet Culture and Transduction

Human islets were received from one of the several Islet Cell Resource (ICR) Centers
in culture media at 4°C. On receiving, the islets were cultured in CMRL-1066 medium
containing 10% fetal bovine serum (FBS) and 1% Penicillin Streptomycin. Islets were
then transduced with Adv-hVEGF-hIL-1Ra, while non-transfected islets as well as the
islets transfected with phVEGF-hIL-1Ra/Lipofectamine complexes (3/1, +/-, 2.5µg
DNA/1000 islets) were used as controls. To determine the optimal multiplicity of
infection (MOI) of Adv vectors in terms of plaque forming units (pfu) per cell of an islet
which is a cluster of 1000 cells, 1000 islets were incubated with Adv-hVEGF-hIL-1Ra in
300μl media in a 96 well plate for 12h, followed by washing and further culturing in 1ml
of media in 24-well plates. Gene expression was determined at day 1 and 3 by
quantifying secreted protein in the media by ELISA (R&D Systems). Total protein of the
islet cell extracts was also determined using the bicinchoninic acid (BCA) protein assay
kit.
2.2.6.

Quantitative Real time PCR

To determine hVEGF and hIL-1Ra gene expression 3 days after transduction with
Adv-hVEGF-hIL-1Ra, the islet pellet was collected for isolation of total RNA using
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RNAeasy mini isolation kit from Promega. Two hundred and fifty nanograms (ng) of
extracted RNA was converted into cDNA using MultiScribe reverse transcriptase and
random hexamers (Applied Biosystems, Inc.) by incubation at 25°C for 10 min, followed
by reverse transcription at 48°C for 30 min and enzyme inactivation at 95°C for 5 min. In
all 3.85μl of cDNA was amplified by real time RT-PCR. To determine the level of
hVEGF expression due to Adv-hVEGF-hIL-1Ra transduction, while excluding the
endogenous expression, Adv vector specific reverse primer (5’-TAG CCA GAA GTC
AGA TGC TCA AGG-3’) was designed from the PolyA region specific to the vector.
The forward primer (5’-TTT CTG CTG TCT TGG GTG CAT TGG-3’) was designed
from the hVEGF gene sequence. We also designed both primers from the gene: forward
(5’-TTT CTG CTG TCT TGG GTG CAT TGG-3’) and reverse (5’-AAG ATG TCC
ACC AGG GTC TCG AAT-3’) so that cumulative expression of hVEGF can be
determined.
In case of hIL-1Ra both, forward (5’-ATC CAG CAA GAT GCA AGC CCT-3’) and
reverse (5’-TTC GTC AGG CAT ATT GGT GAG GCT-3’) primers were designed from
the gene sequence (NCBI Accession#AK290898). To determine the level of hIL-1Ra
expression excluding its endogenous expression, forward primer was designed from the
Adv sequence (5’-AGC CTC ACC AAT ATG CCT GAC GAA-3’) and reverse primer
from the gene sequence (5’-TTG CCA TGC AAG AAT GGG AAC AGG-3’) (NCBI
Accession#AB021221). The PCR conditions included denaturation at 95°C for 10 min,
followed by 40 cycles of amplification by sequential denaturation at 95°C for 15 sec and
primer annealing as well as strand extension for 1 min.
To confirm the amplification specificity, the PCR products were subjected to melting
curve analysis. hVEGF and hIL-1Ra gene expression was normalized to 18s rRNA as
internal control. Threshold cycle number was compared between Adv-hVEGF-hIL-1Ra
with the same parameters using non-transfected islets as controls.
2.2.7.

In Vitro Islet Function after Transduction

The in vitro islet function after transduction with Adv-hVEGF-hIL-1Ra was
determined by the static incubation method, using non-transduced islets as control.
Transfection media was removed and the islets were sequentially incubated at 37ºC for
1h in the media containing 2.5mM (basal) and 22mM glucose (stimulated). After
incubation, supernatants were collected and analyzed for insulin release by ELISA
(Alpco Diagnostics). Insulin secretion was expressed as µU/ml and the ratio of insulin
levels at 22mM to 2.5mM glucose was used to calculate the stimulation index.
2.2.8.

Cytoprotective Effect of Adv-hVEGF-hIL-1Ra

One thousand islets per well of 96 well plates were transduced with 1000 MOI of
Adv-hVEGF-hIL-1Ra, Adv-hVEGF or Adv-hIL-1Ra. At 12h post-transduction, islets
were washed and incubated with either fresh media or a cocktail of IL-1β (10ng/ml),
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TNF-α (10ng/ml) and IFN-γ (50ng/ml). At day 3 post transduction islets were collected
from each well and lysed with lysis buffer to measure the caspase-3 concentration using
the Caspase-Glo 3/7 Assay kit (Madison, WI).
We also determined the cytoprotective effect of Adv-hVEGF-hIL-1Ra on islet
viability by fluorescence microscopy of islets after transduction with Adv-hVEGF-hIL1Ra (500, 1000 and 2000 MOI), Adv-hVEGF (1000 MOI), and Adv-hIL-1Ra (1000
MOI) for 12h, followed by incubation with the cytokine cocktail for 3 days. These islets
were stained with propidium iodide (500nM) to identify dying or dead cells under
fluorescence microscope (Olympus).
2.2.9.

Islet Transplantation Studies

Animal experiments were performed as per the NIH
(http://grants1.nih.gov/grants/olaw/ references/phspol.htm) and institutional animal care
and use guidelines using approved protocols. To establish the diabetic animal model,
streptozotocin (STZ) (40mg/kg) was administered to NOD-SCID mice by intraperitoneal
injection for 5 consecutive days. Animals were considered to be diabetic after two
consecutive blood glucose measurements≥325mg/dl using a One Touch Ultra
Glucometer (Lifescan, Milipitas, CA). Before transplantation, human islets were
transduced by Adv-hVEGF-hIL-1Ra or Adv-LacZ at the dose of 1000 MOI for 12h and
washed with PBS. About 1500 transduced or non-treated islets were transplanted under
the left kidney capsules of diabetic mice. The nonfasting glucose levels were measured
up to 20 days post-transplantation. The mice were then anesthetized to collect blood to
measure serum insulin by ELISA and C-peptide by radioimmunoassay (Diagnostic
Products Corp.). The graft-bearing kidneys were removed to confirm the function of islet
grafts by the return to blood glucose levels to325mg/dL for two consecutive days.
2.2.10. Immunohistochemistry and Morphometric Analysis
To determine hVEGF expression and angiogenesis, transplanted mice were
sacrificed, kidneys were isolated, washed with PBS, fixed in 4% formaldehyde overnight,
and embedded in paraffin as described before.133 Sections of 5-7µm thickness were cut
and immunostained with rabbit anti-insulin, hVEGF and hvW primary antibodies,
respectively. The immunoreactivity was detected using goat anti-rabbit IgG, H&L chain
specific peroxidase conjugate and subsequent incubation with DAB substrate. For
morphometric analysis, hVEGF and hvWF-positively immunostained color (brown in
each case) was selected for quantification of the relative intensity using NIH Image 1.62
software to determine the mean values, which were subsequently compared between
Adv-hVEGF-hIL-1Ra transduced and control islet transplanted diabetic recipient mice.
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2.2.11. Statistical Analysis
Statistical significance of the difference between the two groups was determined by
unpaired t-test and between several groups by one-way ANOVA.
2.3.

Results
The results of the study are discussed below.

2.3.1.

Construction of Adv-hVEGF-hIL-1Ra

Adv-hVEGF-hIL-1Ra is a serotype 5 based replication deficient Adv vector that
contains a CMV promoter, hVEGF cDNA and rabbit β-globin polyA in the E-1 region
and a CMV promoter, hIL-1Ra cDNA and rabbit β-globin polyA in the E-3 region
(Figure 2-1). Both cassettes are oriented from left to right relative to the adenovirus
genome and lack the CMV intron that was present in the cosmid pADhVEGF-hIL-1Ra,
from which no virus could be recovered. hVEGF and hIL-1Ra coding sequences and
polyA signals were placed under the control of a separate CMV promoter cloned into
pE1.2 and pE3.1. The resulting vectors were combined in Adenoquick 13.1 to generate a
cosmid that contains the entire sequence of recombinant adenovirus. The presence of
hVEGF and hIL-1Ra expression cassettes in these vectors was confirmed by restriction
digestion with Hind III and NotI. The number of viral particles in the stock solution of
Adv-hVEGF-hIL-1Ra was determined by OD260–SDS method. This gives the total
number of 1.2X1012 viral particles per ml of the stock solution irrespective of their plaque
forming ability. The infectious titer of Adv-hVEGF-hIL-1Ra (8X1010 IU/ml) was
calculated by plaque assay method. This was further ascertained by performing the
adenotiter assay using an Adeno X rapid titer kit and the titer was calculated to be 6X109
ifu/ml (infectious units/milliliter). We used infectious units/ml viral titer for all the
experiments.
2.3.2.

Transduction Efficiency of Adv-hVEGF-hIL-1Ra

Following transduction of islets with Adv-hVEGF-hIL-1Ra, the level and duration of
hVEGF and hIL-1Ra proteins increased with increase in MOI. hVEGF and hIL-1Ra
protein levels at day 3 post-transduction was over 100 times more than that of the
untransduced islets (Figure 2-2), indicating that Adv-hVEGF-hIL-1Ra transduction
would lead to high local concentrations of hVEGF and hIL-1Ra in the immediate vicinity
of islets post transplantation. We also transfected islets with the bipartite plasmid DNA
encoding these two genes (phVEGF-hIL-1Ra) after complex formation with
Lipofectamine, which produced about 100 times lower levels of hVEGF and hIL-1Ra
proteins than that of the islets transduced with Adv-hVEGF-hIL-1Ra (Figure 2-2).
We also determined hVEGF and hIL-1Ra gene expression by real time RT-PCR. The
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Figure 2-1

Construction of E1 and E3 deleted Adv-hVEGF-hIL-1Ra.

Construction of E1 and E3 deleted bipartite Adv vector by cloning hVEGF and hIL1Ra into the multiple cloning sites of shuttle plasmids pE3.1 and pE1.2. These expression
cassettes were cloned into AdenoQuick plasmid 13.1 to generate a cosmid containing the
entire sequence of recombinant adenovirus. After transfection into 293 cells, AdvhVEGF–hIL-1Ra was produced.
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Time profile of hVEGF and hIL-1Ra at protein levels.

Time profile of hVEGF and hIL-1Ra gene expression at protein levels in human islets
transduced Adv-hVEGF-IL-1Ra at different multiplicities of transduction (MOI) 100,
500, 1000, 2000 and 5000 per 1000 islets. Non-transfected islets as well as the islets
transfected with phVEGF-hIL-1Ra/Lipofectamine complexes (3/1, +/-, 2.5µg DNA/1000
islets) were used as controls. ELISA of cell culture supernatants were performed at days
1 and 3. Cumulative expression levels were presented as the mean±S.D. of n=4. *p<0.05
compared with untransduced islets using ANOVA.
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normalized mRNA concentration to that of the control was significantly increased with
increase in MOI of Adv-hVEGF-hIL-1Ra (Figure 2-3). Gene expression at mRNA level
of hVEGF and hIL-1Ra was more than 100 times higher than that of untransduced islets.
Islets transfected with the bipartite plasmid, phVEGF-hIL-1Ra, also produced very low
levels of hVEGF and hIL-1Ra mRNA. Each graph is indicative of the relative increase in
expression of hVEGF and hIL-1Ra independently. This shows that Adv-hVEGF-hIL-1Ra
can simultaneously express both genes with high efficiency. The mRNA levels of
hVEGF and hIL-1Ra obtained by using one primer from the gene and the other from the
Adv backbone showed dose dependent increase signifying that these genes were being
expressed by Adv-hVEGF–hIL-1Ra (data not shown). The mRNA concentrations of each
gene were normalized to that of the untransduced islets. The amplification specificity was
confirmed by melting peak analysis, which showed a single predominant peak each for
18s (85.4°C), hVEGF (84.5°C) and hIL-1Ra (87.05°C), respectively (data not shown).
2.3.3.

Effect of Viral Transduction on Islet Function

To determine whether insulin secretion was adversely affected by transduction of
islets with Adv-hVEGF-hIL-1Ra, insulin secretion in response to glucose challenge was
carried out at day 5 post-transduction. Glucose challenge was determined by quantifying
glucose stimulated insulin release at basal level (2.5mM) and stimulated (22mM) glucose
concentrations. As shown in Figure 2-4 stimulation index was almost identical to that of
untransduced islets when 1000 islets were treated with Adv-hVEGF-hIL-1Ra at the dose
of 1000 MOI. However, when 1000 islets were treated with this vector at 2000 MOI,
there was some cytotoxicity resulting in decreased stimulation index.
2.3.4.

Apoptosis of Islets

Apoptosis of islets leading to their impaired function and subsequent death is an
important detriment to islet transplantation. Caspase-3 plays a major role in the apoptosis
of islets. Therefore, we determined caspase-3 level in the islets transduced with AdvhVEGF-hIL-1Ra and incubated with a cocktail of inflammatory cytokines such as IL-1β,
TNF-α and IFN-γ. Caspase-3 activity was very high in the un-transducted islets treated
with the cytokine cocktail compared to that in the absence of the cytokine cocktail
(Figure 2-5). The islets treated with 1000 and 2000 MOI Adv-hVEGF-hIL-1Ra and AdvhIL-1Ra showed significantly lower levels of caspase-3 activity compared to the
untransduced control islets or the islets transducted with Adv-hVEGF at 1000 MOI and
incubated in the cytokine cocktail (Figure 2-5). In contrast, caspase-3 activity of all
groups was very low when these islets were not incubated with the cytokine cocktail,
suggesting that the Adv vector was non-toxic to islets at these tested doses.
We also determined the cytoprotective effect of Adv-hVEGF-hIL-1Ra on islet
viability by fluorescence microscopy after transduction and incubation with the cytokine
cocktail. These islets were stainied with propidium iodide, which is known to be
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Real time PCR of islets transduced with Adv-hVEGF-IL-1Ra.

Real time PCR of human islets at day 3 post transduction with Adv-hVEGF-IL-1Ra
at MOI of 100, 500, 1000, 2000 and 5000. Forward and reverse primers were designed
from hIL-1Ra and hVEGF genes. Non-transfected islets as well as the islets transfected
with phVEGF-hIL-1Ra/Lipofectamine complexes (3/1, +/-, 2.5µg DNA/1000 islets) were
used as controls. Cell pellet was collected at day 3 and processed for mRNA extraction,
reverse transcription and real time PCR using SYBR green chemistry. The normalized
mRNA values of the different MOI treated islets are plotted. Since different primers were
used, no direct comparison can be made, other than demonstration of increase in mRNA
levels with increase in MOI. Results are expressed as the mean S.D of n=4 *P<0.05
compared with control using ANOVA.
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Stimulation indexes (SI) of human islets with or without cytokine incubation after
transduction with Adv-hVEGF-IL-1Ra. Non-transduced (N) islets were used as controls.
Results are expressed as the mean±S.D of n=3. *P value compared to untransduced islets.
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Effect of Adv-hVEGF-hIL-1Ra expression on caspase-3 activity.

Caspase-3 activity in human islets in the absence of or after incubation with the
cytokines was determined by measuring the amount of caspase-3 present in the lysate of
islets after cell lysis using a Caspase-Glo 3/7 luciferase assay. The islets were transduced
with Adv-hVEGF-hIL-1Ra, at Adv-hVEGF or Adv-hIL-1Ra prior to incubating with
cytokines IL-1β (10ng/ml), TNF-α (10ng/ml) & INF-γ (50ng/ml). Non-transduced islets
were used as control. Mean±S.D. of n=3, *p value compared with cytokine treated nontransduced islets using ANOVA.
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excluded by viable cells but can penetrate cell membranes of dying or dead cells, as
evidenced red staining. As shown in Figure 2-6, the number of red cells was significantly
lower in all the groups which were not incubated with the cytokine cocktail. However,
incubation with the cytokine cocktail significantly increased the number of red cells in
case of untransduced control islets. However, transduction of islets with Adv-hVEGFhIL-1Ra and Adv-hIL-1Ra significantly decreased the number of red cells even after
incubation with the cytokine cocktail, suggesting the protective effect of hIL-1Ra gene
expression. These results corroborate well with the results shown in Figure 2-5 for the
effect of Adv-hVEGF-hIL-1Ra on caspase-3 activity.
2.3.5.

Islet Survival and Function after Transplantation

The effect of hVEGF and hIL-1Ra gene expression on the islet survival and function
post-transplantation of 1500 islets transduced with Adv-hVEGF-hIL-1Ra at 1000 MOI
under the kidney capsules of NOD-SCID mice was determined in terms of blood glucose,
human insulin, and C-peptide levels. Diabetes was partly corrected in higher number of
mice receiving Adv-hVEGF-hIL-1Ra transduced islets as compared to those receiving
Adv-LacZ transfected and non-treated islets. Adv-hVEGF-AdvhIL-1Ra transduced islets
showed much rapid reduction in blood glucose levels to220mg/dl (3 days) than AdvLacZ transduced or non-treated islets. Mice transplanted with Adv- hVEGF-hIL-1Ra
transduced islets had the lowest blood glucose levels, followed by non-treated islets
(Figure 2-7A). Blood glucose levels returned to325mg/dL upon removal of the islet
graft-bearing kidney at days 21 after transplantation, confirming that transplanted islets
were functional. Upon glucose challenge, both blood insulin and C-peptide levels were
significantly higher in mice transplanted with Adv-hVEGF-hIL-1Ra transduced islets
compared to all the other groups, indicating better islet engraftment and function
(Figure 2-7B, C). These results suggest that compared to non-treated or Adv-LacZ
transduced islets, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level
of mice, and increased the level of blood insulin and c-peptide upon glucose challenge.
2.3.6.

Immunohistochemistry

To determine whether hVEGF gene expression after transduction with Adv-hVEGFhIL-1Ra will promote angiogenesis by human islets, we isolated the kidney bearing AdvhVEGF-hIL-1Ra transduced islets at 20 days post-transplantation into diabetic NODSCID mice for sectioning and staining with polyclonal rabbit hVEGF and vonWillebrand
Factor (hvWF) antibodies. Staining with anti-human insulin and untransduced islet
sections were used as the controls. The positive staining of hVEGF was higher in the
transduced islets compared to untransduced islets (Figure 2-8), suggesting efficient
hVEGF gene expression after transduction with Adv-hVEGF-hIL-1Ra. The positive
staining of hvWF factor was more evident in Adv-hVEGF-hIL-1Ra transduced islets,
which is an indicator for endothelial cells. Morphometric analysis revealed that AdvhVEGF-hIL-1Ra transduced Islet grafts exhibited higher hVEGF and hvWFimmunostaining and intensity than control islet grafts, with relative intensities of 1.45 vs.
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Figure 2-6

Effect of hVEGF and hIL-1Ra co-expression on islet viability.

Effect of hVEGF and hIL-1Ra co-expression on islet viability was examined under
fluorescence microscopy after propidium iodide staining of intact islets transduced with
Adv-hVEGF-hIL-1Ra, Adv-hIL-1Ra and Adv-hVEGF, and then incubated for 3 days
with inflammatory cytokines. Red staining represents cell membranes of dying or dead
cells.
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Transplantation of Adv-hVEGF-hIL-1Ra transduced islets.

Following transduction with Adv-hVEGF-hIL-1Ra at 1000 MOI, 1500 islets were
transplanted under the kidney capsule of streptozotocin-induced diabetic NOD-SCID
mice. The mice transplanted with Adv-LacZ-transduced and non-transduced islets were
used as controls. A) The nonfasting glucose levels were measured in each animal up to 20
days post-transplantation using a One Touch Ultra Glucometer. Blood glucose levels
returned to325mg/dL upon removal of the islet graft-bearing kidney at days 21 after
transplantation. B&C). At day 21 post-transplantation, the mice were sacrificed and blood
was collected to measure serum insulin by ELISA and C-peptide by radioimmunoassay
(RIA). Data are presented as the mean+S.D. of n=4, *p<0.5, compared to Adv-hVEGFhIL-1Ra transduced islet group.
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Immunohistochemical staining of islet bearing kidney sections.

Immunohistochemical staining of islet bearing kidney sections at day 20 posttransplantation of human islets transduced with Adv-hVEGF-hIL-1Ra at 1000 MOI.
Rabbit polyclonal anti human VEGF and hvW were used for detecting human VEGF and
endothelial cells. These pictures were taken at x40 magnification. A) Insulin, B) hVEGF
and C) vWF staining for the islets transduced with Adv-hVEGF-hIL-1Ra; and D) insulin,
E) hVEGF and F) hvWF staining for the control islets.
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1 for hVEGF and 1.30 vs. 1 for hvWF, respectively. To correlate the degree of islet
revascularization with the islet mass in the kidney capsule, we also stained for human
insulin. Adv-hVEGF-hIL-1Ra transduced islets displayed significantly higher levels of
insulin content than control islet groups (Figure 2-8B), with relative intensity of 1.3 vs. 1.
This quantitative difference in insulin content in the kidney capsule between AdvhVEGF-hIL-1Ra transduced and control islet groups of diabetic recipient mice correlated
well with their blood glucose, serum insulin and c-peptide profiles (Figure 2-7). The
positive staining for human insulin also confirmed the functionality of islets. These
results indicate the beneficial effect of Adv-hVEGF-hIL-1Ra for the islet survival and
function post-transplantation.
2.4.

Discussion

Isolation and purification of islets disrupt their microvasculature, leading to hypoxia
and apoptosis upon transplantation.133 We and others have shown that hVEGF expression
promotes new blood vessel formation and improves the outcome of islet
transplantation.18,133 However, effective prevention of islet destruction after
transplantation requires not only revascularization but also abrogation of cytokine
mediated islet cell death and dysfunction. Islet injury stimulates resident macrophages
and infiltrating leukocytes to produce cytotoxic cytokines like IL-1β, TNF-α and IFN-γ.
Among these cytokines, IL-1β is the key mediator of β cell destruction.
Administration of recombinant IL-1Ra protein has been shown to prevent islet
dysfunction upon transplantation.151 Ex vivo transduction of human islets with Adv-hIL1Ra has been reported to prevent IL-1β induced β cell impairment and activation of islet
cell apoptosis.150 Therefore, we recently transduced human islets with a mixture of AdvhVEGF and Adv-hIL-1Ra133 and demonstrated suppression of cytokine induced iNOS
gene expression and NO production.133,152 Similarly, Bertera et al.,153 reported synergistic
effect after simultaneous Adv transduction of mouse islets with two individual genes,
such as IL-1Ra and indoleamine 2, 3 dioxygenase or hIL-1Ra and manganese superoxide
dismutase (MnSOD).
The objective of this study was to evaluate a bipartite Adv vector for multiple gene
delivery to human islets for promoting revascularization and inhibiting inflammatory
cytokine–mediated destruction. There are several studies where bipartite Adv vectors
have been constructed with one therapeutic gene and another marker gene, especially
green fluorescence protein (GFP).154,155 In this study, we have constructed a replication
deficient bipartite Adv vector encoding hVEGF and hIL-1Ra. The use of bipartite vector
not only simplifies the amplification and purification process of Adv vectors, but also
decreases the use of total Adv backbone. This is expected to minimize the immunogenic
and toxic effects of Adv vectors. hVEGF is known to promote angiogenesis156 and
improved vascularization can lead to reduced apoptosis. On the other hand, hIL-1Ra
inhibits apoptosis of islets.151 Apoptosis begins during the islet isolation process, peaks 23 days post transplantation, and continues for approximately 7~14 days until what
remains of the graft has stabilized and become vascularized. Therefore, the use of
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replication deficient Adv vectors is appropriate. We decided to use ∆E1 and ∆E3 Adv
vector because our goal was to achieve transient gene expression, while avoiding other
potential side effects and in vivo virus replication. To determine hVEGF and hIL-1Ra
gene expression, we first transduced human islets with Adv-hVEGF-hIL-1Ra and then
monitored transgene expression for 3 days. hVEGF and hIL-1Ra expression over days 1
and 3 showed considerable increase (Figure 2-2), suggesting the efficacy of Adv-hVEGFhIL-1Ra. Variation in MOI, promoters and duration of the incubation time are known to
affect the transfection efficiency of Adv vectors in various cell types. Therefore, we
sought to optimize the transduction conditions of human islets with Adv-hVEGF-hIL1Ra. hVEGF and hIL-1Ra gene expression increased with increase in MOI from 100 to
5000. However, we decided to infect 1000 islets with this vector at 1000 MOI to avoid
any toxic side effects. Unlike the Adv vector, transfection with the bipartite plasmid
encoding hVEGF and hIL-1Ra (p-hVEGF-hIL-1Ra) produced very little hVEGF and
hIL-1Ra (Figure 2-2) which is consistent with our previous results18 and is expected since
an islet is a cluster of 200-1000 cells and difficult to transfect.
Since prolonged incubation with Adv vectors may induce apoptosis and loss of
endothelial cells; we decided not to co-culture the islets beyond 12h. We then determined
hVEGF and hIL-1Ra gene expression at mRNA level for which we used 18s as an
internal control. The mRNA levels of hVEGF and hIL-1Ra increased with increase in
MOI (Figure 2-3), indicating the Adv vector is indeed expressing these two genes as
desired. Although hVEGF and hIL-1Ra increased at both protein and mRNA levels with
increase in the Adv MOI, these results cannot be directly correlated. Unlike ELISA, we
used different primers for different genes (in this case hVEGF and hIL-1Ra) and thus we
can only compare the results relative to the house keeping genes. Also, it is known that
there is a poor correlation between mRNA and protein levels. That is why we have to use
house-keeping genes whenever we do real time PCR. Jansen et al., have hypothesized
that low correlation of protein and mRNA levels are a result of post translational
modifications.157
Transduction process should not affect the normal insulin secretion capacity of
human islets, which varies from batch to batch. Therefore, we measured insulin release in
response to glucose challenge to assess the islet functional viability. As shown in Figure
2-4, there was little decrease in the stimulation index when islets were transduced with
Adv-hVEGF-hIL-1Ra at the dose of 1000 MOI per 1000 islets. These data indicate that
transduction with Adv-hVEGF-hIL-1Ra had only minimal adverse effect on insulin
producing β cells of the islets in response to glucose challenge.
Several studies have shown little induction of inflammatory responses on islet
apoptosis when islets are transduced with Adv vectors at low MOI, which is also true in
our studies. Since we wash islets with PBS to remove any free viral particles prior to
transplantation and these vectors being replication deficient, we do not expect the host to
mount a rigorous immune response. While there will be no free viral particles with the
transplanted islets, even direct administration of this dose of Adv vectors have been seen
to be non-toxic. Studies of Crystal and coworkers further showed local delivery of low
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and intermediate doses of replication deficient Adv vectors (1011 particles) well
tolerated.158
Most islet grafts are destroyed due to immune and inflammatory reaction mediated by
proinflammatory cytokines. To mimic the in vivo situation of the cytokine mediated
insults we incubated islets with a cocktail of IL-1β, TNF-α and INF-γ. Incubation with
the inflammatory cytokines induced apoptosis in islets indicated by the increase in
caspase-3 (Figure 2-5), which is a converging point of apoptosis for intrinsic and
extrinsic pathways and caspase-6 and 7 are generated from caspase-3. However, the islets
treated with 1000 and 2000 MOI Adv-hVEGF-hIL-1Ra and Adv-hIL-1Ra showed
significantly lower levels of caspase-3 activity compared to the untransduced islets or the
islets transducted with Adv-hVEGF at 1000 MOI and incubated in the cytokine cocktail,
possibly due to hIL-1Ra gene expression (Figure 2-5). Similarly, incubation of islets with
the cytokine cocktail significantly increased the number of red cells indicating dying or
dead cells (Figure 2-6), which was much less for the islets transduced with Adv-hVEGFhIL-1Ra or Adv-hIL-1Ra, even after incubation with the cytokine cocktail. These results
are well correlated with the literature where Adv vector encoding IL-1Ra150 as well as
recombinant IL-1Ra159 have shown to protect islets from inflammatory cytokines. In
contrast, there was no increase in caspase-3 after transduction of islets with Adv-hVEGFhIL-1Ra, Adv-hIL-1Ra or Adv-hVEGF in the absence of inflammatory cytokines,
suggesting these Adv vectors are fairly safe at these tested doses.
Effect of Adv-hVEGF-hIL-1Ra transduction on improvement in the survival and
function of islets posttransplantation was determined in streptozotocin-induced diabetic
NOD-SCID mice. We observed a reduction in blood glucose levels of mice transplanted
with Adv-hVEGF-hIL-1Ra transduced islets than that observed with Adv-LacZtransduced or non-treated islets (Figure 2-7A). This increase correlated with the higher
amount of serum insulin and C-peptide secreted by the islets at day 20 posttransplantation (Figure 2-7B and C). These results indicate that hVEGF and hIL-1Ra coexpression is likely to reduce the islet mass required to achieve normoglycemia.
Although we did not examine the apoptosis in graft islet cells, our in vitro data clearly
indicated transduction of Adv-hVEGF-hIL-1Ra led to significant reduction of caspase-3
activity, which is the indicator of apoptosis.
Revascularization of islet grafts after transplantation is an important process that
influences long-term survival and function of the grafts. Endothelial cells reside within
isolated islets and potentially participate in the revascularization process.
Immunohistochemical staining in the islet bearing kidney sections at day 20 after
transplantation was positive for human insulin, hVEGF and hvWF (Figure 2-8). Positive
staining for insulin, which stains pancreatic -cells, corroborates the blood insulin data
and confirms that islets are indeed functional after transplantation, which is in good
agreement with the contemporary literature. hvWF is human endothelial cell marker.
Therefore, relatively stronger positive staining for hVEGF and hvWF antigens by the
Adv-hVEGF-hIL-1Ra transduced islet bearing kidney section groups indicates that blood
vessel formation in the transplanted islets was relatively more efficient when islets were
transduced with Adv-hVEGF-hIL-1Ra prior to transplantation. This indicates the
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usefulness of this adenoviral vector in improving the survival and function of islets after
transplantation.
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CHAPTER 3. BIPARTITE ADENOVIRAL VECTOR ENCODING hHGF AND
hIL-1Ra FOR IMPROVED HUMAN ISLET TRANSPLANATATON
3.1.

Introduction

Type I diabetes is a chronic inflammatory autoimmune disease resulting from the loss
of islet function, requiring life-long insulin therapy. Human islet transplantation has the
potential to replace pancreatic endocrine function in patients with Type I diabetes 160,161
One major drawback to this approach is the requirement of islets derived from two to
four cadaver donors to treat a single patient with diabetes. In addition, required islet mass
has been seen in successfully transplanted recipients compared with healthy people162
Thus, an enormous shortage of human islets is a barrier to the use of islet transplantation
on a larger scale. Despite recent success, islet transplantation still lags behind primarily
because a large number of transplanted islets often do not function.143
Islets have an intricate microvasculature, which is disrupted during islet isolation and
purification process. Therefore, revascularization to the transplanted islets is essential for
delivery of nutrients and oxygen to the inner core of islets for their survival.100,133,144,163
Hepatocyte growth factor (HGF) is a potent mitogen for human islets and is known to
increase the proliferation and expansion of -cells and promotes revascularization of
islets, while maintaining physiologic glucose responsiveness after transplantation.104
Overexpression of HGF in the -cells of transgenic mice directed by the rat insulin Type
II promoter (RIP) has shown to increase -cell mass and proliferation, and improve islet
function and islet transplant outcome.164 Ex vivo transduction of islets with an adenoviral
(Adv) vector encoding HGF has been reported to improve the outcome of islet
transplantation.165 Intravenous injection of Adv-HGF in streptozoticin (STZ)-induced
diabetic mice have been shown to ameliorate hyperglycemia and prolong survival period
in the diabetic mice.166 Moreover, HGF gene transfer has also been shown to increase the
expression of three key β-cell genes, glucokinase, Glut-2 (the β-cell glucose transporter),
and insulin.167
Success of islet transplantation not only depends on islet revascularization, but also
on its protection from apoptosis induced by hypoxia, oxidative stress and inflammatory
cytokines released from resident macrophages and infiltrating immune cells at the
transplantation site.147 More than 70% of islets become inactive in 7-14 days posttransplantation.168 Among these cytokines, IL-1β plays a key role in apoptotic cell death.
Inhibition of IL-1β receptor binding using interleukin-1 receptor antagonist (IL-1Ra)
resulted in improved islet survival and function.149-151 HGF has also been reported to
induce resistance to apoptosis.169
Considering the favorable uses of hHGF and hIL-1Ra, in this study we constructed a
bipartite Adv vector encoding these two genes (Adv-hHGF-hIL-1Ra) by cloning hIL-1Ra
and hHGF under a separate cytomegalovirus (CMV) promoter. We determined
transduction efficiency, islet function, and caspase-3 release upon incubation with
inflammatory cytokine cocktail of TNF-α, IL-1β and IFN-γ. We then transplanted islets
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under the kidney capsules of nonobese diabetic/severe combined immunodeficient
(NOD-SCID) mice after transduction with Adv-hHGF-hIL-1Ra and determined the levels
of blood glucose and serum insulin. Finally, the islet bearing kidney sections of these
diabetic mice were stained for human insulin, hHGF and von Willebrand factor (vWH).
3.2.
3.2.1.

Materials and Methods
Materials

Agarose, tris-borate-EDTA buffer, goat serum, glucose and haematoxylin solution
were purchased from Sigma-Aldrich Co. (St. Louis, MO). Fetal bovine serum (FBS) and
CMRL-1066 media were purchased from MediaTech Cellgros (Herndon, VA). Phosphate
buffer solution (PBS) was purchased from GIBCO-BRL (Gaithersburg, MD). Human
HGF and IL-1Ra ELISA kits and cytokines IL-1β, TNF-α and IFN-γ were purchased
from R&D Systems (Minneapolis, MN). Human Insulin ELISA kits were purchased from
Alpco Diagnostics (Windham, NH). RNA extraction kit and Caspase-Glo 3/7 assay kit
were procured from Promega (Madison, WI). SYBR Green real time PCR master mix
and reverse transcription reagents were purchases from Applied Biosystems (Foster City,
CA). Sodium citrate was procured from Curtin Matheson Science Inc. (Houston, TX.)
3.2.2.

Methods

The following methods were used with regards to generation of the adenoviral vector
and testing its efficacy both in vitro and in vivo.
3.2.3.

Construction of Adv-hHGF-hIL-1Ra

A bipartite Adv vector expressing hHGF and hIL-1Ra genes was constructed with the
help of OD 260, Inc. (Boise, ID). Briefly, the hHGF cDNA was excised from pCMVhHGF using BamHI, and cloned into the BamHI site of pE1.2, which contains a CMV
promoter, multiple cloning site, and bGH polyA signal. Similarly, hIL-1Ra cDNA was
excised from pUMVC-hIL-1Ra vector using ScaI, separated by gel fractionation, and
purified using Promega PCR and cleanup kit (Promega, Madison, WI). The hIL-1Ra
fragment along with rabbit β-globin polyA was then cloned into pE3.1 shuttle plasmid
using NotI restriction site. The pE 3.1 IL-1Ra plasmid was further modified by removing
the intron adjoining CMV promoter. All the ligation reactions were done at 1:3 and 1:10
ratios using T4 DNA ligase and then transformed in super competent TOP 10 cells and
amplified in terrific broth media. The plasmids were then purified using Gen Elute
plasmid Mini prep kit (Sigma-Aldrich, St. Louis, MO). The plasmids pE 1.2-hHGF and
pE 3.1-hIL-1Ra were digested with AlwNI and DraIII respectively and the excised
fragments were purified on agarose gel. These fragments were ligated with SfiI-digested
AdenoQuick 13.1 plasmid simultaneously using T4 DNA ligase overnight at 16ºC. The
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ligated products were packaged into phage lambda particles using MaxPlax packaging
extract (Epicentre, Madison, WI). The packaging mixture was used to infect E. coli XL1Blue (Stratagene) and clones were selected on LB supplemented with 25µg/ml
kanamycin and 50µg/ml ampicillin. The Pac I linearized cosmid was transfected into 293
cells to rescue the virus. Three viral plaques were amplified, and their genomic DNAs
were extracted. The presence of hHGF and hIL-1Ra expression cassettes in these three
vectors was confirmed by restriction analysis with SpeI and EcoRV, respectively. The
clone containing the two genes was infected to 293 cells. Both the cells and the medium
were harvested and frozen/thawed three times. This viral extract was further infected into
293 cells, amplified and purified on two CsCl gradients. The bands harvested were
dialyzed against 3X1 l GTS buffer (25% glycerol, 25mM NaCl, 20mM Tris-HCl (pH 8)
for 12 hours at 4ºC. The dialyzed viral suspension was collected, filtered and stored at
-70ºC.
3.2.4.

Determination of Viral Titer

The infectious viral titer was also determined by using an Adeno-X rapid titer kit
from Clontech (Mountain View, CA). Different dilutions of Adv-HGF-hIL-1Ra was
taken and transduced to AD-293 cells, using un-transduced cells as a control. After 48h
post-transduction, AD-293 cells were fixed and incubated with Anti-Hexon antibody,
followed by a secondary horse radish peroxidase (HRP)-conjugated antibody. Then the
cells were stained with 3, 3’ diaminobenzidine tetrahydrochloride (DAB) substrate and
positively stained cells were counted under a microscope, and the titer was determined.
3.2.5.

Islet Culture and Transduction

Human Islets were received from one of the several Islet Cell Resource (ICR) Centers
in culture media at 4°C. Upon receipt, the islets were cultured in CMRL-1066 medium
containing 10% fetal bovine serum (FBS) and 1% Penicillin Streptomycin. Islets were
then transduced with Adv hHGF-hIL-1Ra, while non-transduced islets were used as
controls. To determine the optimal multiplicity of Infection (MOI) of Adv in terms of
plaque forming units (pfu) per islet equivalent, 1000 islets were incubated with diluted
adenovirus at 100, 500, 1000, 2000 and 5000 MOI in 300μl media in a 96 well plate for
12h, followed by washing and further culture in 1ml of media in 24-well plates. Gene
expression was determined at days 1 and 3 by quantifying secreted protein in the media
by ELISA (R&D Systems, Minneapolis, MN). Total protein of the islet cell extracts was
also determined using the bicinchoninic acid (BCA) protein assay kit to normalize the
results. Three samples per group were included for the experiment.
3.2.6.

Quantitative Real Time PCR

To determine hHGF and hIL-1Ra gene expression in human islets at the mRNA level
by real time RT-PCR, at day 3 post-transduction of islets with Adv-hHGF-hIL-1Ra the
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islet pellet was collected for isolation of total RNA using RNAeasy mini isolation kit
from Promega. RNA concentration was measured by UV spectrophotometry using
Biomate 3 spectrophotometer. Two hundred and fifty nanograms (ng) of extracted RNA
was converted into cDNA using MultiScribe reverse transcriptase and random hexamers
(Applied Biosystems, Inc., Foster City, CA) by incubation at 25°C for 10 min, followed
by reverse transcription at 48°C for 30 min and enzyme inactivation at 95°C for 5 min. In
all 3.85μl of cDNA was amplified by real time RT-PCR. To determine the level of HGF
expression, the following hHGF-specific primers were used: Forward: 5'-CCT ATG CAG
AGG GAC AAA GGA A-3'; Reverse: 5'-GCC TTG CAA GTG AAT GGA AGT CCT-3'
(NCBI Accession#291674). In case of hIL-1Ra both, forward (5’-ATC CAG CAA GAT
GCA AGC CCT-3’) and reverse (5’-TTC GTC AGG CAT ATT GGT GAG GCT-3’)
primers were designed from the gene sequence, (NCBI Accession#AK290898). The PCR
conditions included denaturation at 95°C for 10 min, followed by 40 cycles of
amplification by sequential denaturation at 95°C for 15 sec and primer annealing as well
as strand extension for 1 min. hHGF and hIL-1Ra gene expression was normalized to 19s
rRNA as internal control.
To confirm the amplification specificity, the PCR products were subjected to melting
curve analysis. The expressed HGF and hIL-1Ra levels were quantified and normalized
to the total amount of cDNA used. Threshold cycle number was compared between AdvhHGF-hIL-1Ra with the same parameters using non-transfected islets as controls.
3.2.7.

In Vitro Islet Function after Infection

The in vitro function of human islets after infection with Adv-hHGF-hIL-1Ra was
determined by the static incubation method. Non-infected islets were used as control.
Transfected media was removed by centrifugation at 300g and the islets were
sequentially incubated at 37ºC for 1h in the media containing 2.5mM (basal) and 22mM
glucose (stimulated). After incubation, supernatants were collected and analyzed for
insulin release by ELISA (Alpco Diagnostics). Insulin secretion was expressed as µU/ml
and the ratio of insulin levels at 22mM to 2.5mM glucose was used to calculate the
stimulation index.
3.2.8.

Cytoprotective Effect of Adv-hHGF-IL-1Ra

One thousand islets per well of 96 well plates were infected with 1000 MOI of AdvHGF-hIL-1Ra at 500, 1000 and 2000 MOIs. At 12h post-transduction, islets were washed
and incubated with a cocktail of IL-1β (10ng/ml), TNF-α (10ng/ml) and IFN-γ (50ng/ml)
cytokines. Non-transduced islets with and without cytokine treatment were used as
controls. Blank media was also used the negative control. At day 3 post transduction
islets were collected from each well and were lysed with lysis buffer to measure the
caspase-3 concentration using the Caspase-Glo 3/7 Assay kit (Madison, WI).

49

3.2.9.

Western Blotting

At day 3 post-transduction of human islets with Adv-hHGF-hIL-1Ra, protein extracts
were prepared by washing cells with PBS and lysing in RIPA buffer containing protease
inhibitor (Roche, Basel, Switzerland). Human islets were homogenized and lysates were
spun at 15000g for 15 min to remove insoluble material. Protein concentrations were
determined by BCA protein assay. Proteins were resolved on 4-15% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA) and
transferred to a PVDP membrane (Bio-Rad, Hercules, CA), blocked with TBST buffer
composed of 50mM Tris (pH 7.6), 150mM NaCl and 0.05% Tween supplemented with
5% fat-free milk at 4C for 1h. After a brief rinse, the membrane was incubated overnight
at 4°C in TBST containing 0.5% milk with mouse anti-human Bcl-2 (Santa Cruz, CA)
(1:200) and mouse anti-human Bax (Santa Cruz, CA). Goat anti-human Actin
monoclonal antibody (Santa Cruz, CA) (1:2000) was used for detecting an internal
control protein. Then, blots was washed four times using TBST for 1h at room
temperature. Immunodetection was performed using a horseradish peroxidase (HRP)
Chemi Blot Starter Kit (Bio-rad, Hercules, CA) according to the manufacture’s
instruction.
3.2.10. Islet Transplantation Studies
Animal experiments were performed as per the NIH
(http://grants1.nih.gov/grants/olaw/ references/phspol.htm) and institutional animal care
and use guidelines using the approved protocol. To induce diabetic animal model,
streptozotocin (STZ) (40mg/kg) was administered to NOD-SCID mice by intraperitoneal
injection for 5 consecutive days. Animals were considered to be diabetic after two
consecutive measurements of blood glucose≥300mg/dl using a One Touch Ultra
Glucometer (LifeScan, Inc.). Before transplantation, human islets were transduced by
Adv-hHGF-hIL-1Ra at the dose of 1000 MOI for 12h and washed with PBS. About 1000
transduced or non-treated islets were transplanted under the left kidney capsules of
diabetic mice. The nonfasted glucose levels were measured from the snipped tail of each
animal up to 28 days post-transplantation. At day 28 post-transplantation, the mice were
then anesthetized to collect blood to measure serum insulin and c-peptide levels by
ELISA (Alpco Diagnostics, Salem, NH). At day 28, the graft-bearing kidneys were
removed from some animals to confirm the function of islet grafts by the return of blood
glucose levels to300mg/dL for two consecutive days.
3.2.11. Intraperitoneal Glucose Tolerance Test
Twenty seven days after islet transplantation under the kidney capsules of STZinduced NOD-SCID diabetic mice, glucose tolerance was analyzed in overnight fasted
mice by intraperitoneal injection of 2g of glucose/kg of body weight as described by
Garcia-Ocana et al.165 Blood samples were obtained from the snipped tail and analyzed
for glucose levels using a One Touch Ultra Glucometer (LifeScan, Inc.).
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3.2.12. Immunohistochemistry and Morphometric Analysis
To determine hHGF expression and angiogenesis, transplanted mice were sacrificed,
kidneys were isolated, washed with PBS, fixed in 4% formaldehyde overnight, and
embedded in paraffin as described before.133 Sections of 5-7µm thickness were cut and
immunostained with rabbit anti-insulin, hHGF and hvW primary antibodies, respectively.
The immunoreactivity was detected using goat anti-rabbit IgG, H&L chain specific
peroxidase conjugate and subsequent incubation with DAB substrate. For morphometric
analysis, hHGF and hvWF-positively immunostained color (brown in each case) was
selected for quantification of the relative intensity using NIH Image 1.62 software to
determine the mean values, which were subsequently compared between Adv-hHGF-hIL1Ra transduced and control islet transplanted diabetic recipient mice.
3.2.13. Statistical Analysis
Statistical significance of the difference between the two groups was determined by
unpaired t-test and between several groups by one-way ANOVA.
3.3.

Results
The results obtained from these studies are outlined below.

3.3.1.

Construction of Adv-hHGF-hIL-1Ra

Adv-hHGF-hIL-1Ra is a serotype 5 based replication deficient Adv vector that
contains a CMV promoter, hHGF cDNA and rabbit β-globin poly A in the E-1 region and
a CMV promoter, hIL-1Ra cDNA and rabbit β-globin poly A in the E-3 region (Figure
3-1). hHGF and hIL-1Ra coding sequences and polyA signals were placed under the
control of a separate CMV promoter cloned into pE1.2 and pE3.1. The resulting vectors
were combined in Adenoquick 13.1 to generate a cosmid that contains the entire
sequence of recombinant adenovirus. The presence of hHGF and hIL-1Ra expression
cassettes in these vectors was confirmed by restriction digestion with Hind III (data not
shown). The number of viral particles in the stock solution of Adv-hHGF-hIL-1Ra was
determined using an Adeno X rapid titer kit from Clontech (Mountain View, CA) and the
titer was calculated to be 1.24X10^9 ifu/ml (infectious units/ml).
3.3.2.

Transduction Efficiency of Adv-hHGF-hIL-1Ra

Following the transduction of human islets with Adv-hHGF-hIL-1Ra, the level and
duration of hHGF and hIL-1Ra proteins increased with increase in MOI. hHGF and hIL1Ra protein levels at day 3 post-transduction was over 60 and 40 times higher than that of
the untransduced islets, respectively (Figure 3-2), indicating that Adv-hHGF-hIL-1Ra
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Figure 3-1

Construction of E1 and E3 deleted bipartite Adv-hHGF-hIL-1Ra.

Adv-HGF-hIL-1Ra was constructed by excising hHGF and hIL-1Ra form vector
pUMVC and cloning into the multiple cloning sites of shuttle plasmids pE 3.1 and pE 1.2
using NotI. The expression cassettes of hHGF and hIL-1Ra containing the CMV
promoter were cloned into AdenoQuick plasmid 13.1 to generate a cosmid containing the
entire sequence of recombinant adenovirus. After transfection into 293 cells, recombinant
adenovirus Adv-hHGF–hIL-1Ra was produced.

52

Figure 3-2

Expression of HGF and IL-1Ra genes at protein level.

Time profile of hHGF and hIL-1Ra gene expression at protein levels in human islets
transduced Adv-HGF-IL-1Ra at different multiplicities of transduction (MOI) 100, 500,
1000, 2000 and 5000 per 1000 islets. Non-transduced islets were used as controls. ELISA
of cell culture supernatants were performed at days 1 and 3. Cumulative expression levels
were presented as the mean±S.D. (n=4). N, non-transduced control islets. Difference
between any two groups was determined by ANOVA. P<0.05 was considered statistically
significant.
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transduction would lead to high local concentrations of hHGF and hIL-1Ra in the
immediate vicinity of islets post transplantation. We also determined hHGF and hIL-1Ra
gene expression at mRNA levels by real time RT-PCR. As shown in Figure 3-3, the
normalized mRNA concentration to that of the control was significantly increased with
increase in MOI of Adv-hHGF-hIL-1Ra. Gene expression at mRNA level of hHGF and
hIL-1Ra was more than 60 and 40 times higher than that of untransduced islets,
respectively (Figure 3-3). Each graph is indicative of the relative increase in expression
of hHGF and hIL-1Ra independently. This shows that Adv-hHGF-hIL-1Ra can
simultaneously express both genes with high efficiency. The mRNA concentrations of
each gene were normalized to that of the control i.e., untransduced islets. The
amplification specificity was confirmed by melting peak analysis, which showed a single
predominant peak each for s19 (84.5°C), hHGF (78.8°C) and hIL-1Ra (85.5°C),
respectively (data not shown).
3.3.3.

Effect of Viral Transduction on Islet Function

To determine whether insulin secretion was adversely affected by transduction of
islets with Adv-hHGF-hIL-1Ra, insulin secretion in response to glucose challenge was
carried out at day 3 post-transduction at 500, 1000 and 2000 MOI, while non-transduced
islets were used as the control. Glucose challenge was determined by quantifying glucose
stimulated insulin release at basal level (2.5mM) and stimulated (22mM) glucose
concentrations. There is a significant decrease in the stimulation index of un-transduced
control islets when incubated with the cytokine cocktail compared to that in the absence
of cytokine incubation (Figure 3-4).
Stimulation indices of Adv-hHGF-hIL-1Ra-transduced islets were almost identical to
that of untransduced islets, when they were not incubated with the cytokine cocktail,
suggesting that the transduction process does not cause any harm to the islets. Although
incubation with the cytokine cocktail also led to decrease in the stimulation indices of
Adv-hHGF-hIL-1Ra transduced islets, this decrease was much less compared to that of
the un-transduced control islets, possibly due to the protective effect of hHGF and hIL1Ra co-expression (Figure 3-4).
3.3.4.

Apoptosis of Islets

Apoptosis of islets leads to their impaired function and subsequent death, and thus it
is an important detriment to islet transplantation. Caspase-3 is the converging point of
apoptotic pathways. Therefore, we determined the level of caspase-3 in the islets
transduced with Adv-hHGF-hIL-1Ra, following by incubation with the cytokine cocktail
of IL-1β, TNF-α and IFN-γ. Non-transduced control islets with and without cytokine
treatment were used as controls. As shown in Figure 3-5, caspase-3 activity was high in
the un-transduced islets treated with the cytokine cocktail compared to that in the absence
of the cytokine cocktail. Transduction of islets with Adv-hHGF-hIL-1Ra protected islets
from cytokine induced apoptosis as evidenced by low increase in caspase-3 levels
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Figure 3-3

Real time PCR of Adv-hHGF-hIL-1Ra transduced human islets.

Real time PCR of human islets at day 3 post transduction with Adv-HGF-IL-1Ra at
different MOI of 100, 500, 1000, 2000 and 5000. Forward and reverse primers were
designed from hIL-1Ra and HGF genes. Non-transduced islets were used as controls.
Cell pellet was collected at day 3 and processed for mRNA extraction, reverse
transcription and real time PCR using SYBR green chemistry. The normalized mRNA
values of the different MOI treated islets are plotted. Since different primers were used,
no direct comparison can be made, other than demonstration of increase in mRNA levels
with increase in MOI. N, non-transduced control islets. Difference between any two
groups was determined by ANOVA. P<0.05 was considered statistically significant.
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Figure 3-4

Glucose Stimulation Index.

Stimulation index (SI) of human islets with or without cytokine incubation after
transduction with Adv-hHGF-IL-1Ra at 500, 1000 and 2000 MOI. Non-transduced islets
were used as controls. SI was determined as the ratio of insulin release from islets when
they are incubated at 396mg/dl and 45mg/dl glucose containing media. Increase in insulin
secretion in response to high glucose concentration and decrease with reducing
concentration is significant of metabolically healthy and functional islets. Results are
expressed as a mean±S.D of n=4.
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Figure 3-5

Effect of hHGF and hIL-1Ra co-expression on caspase-3 activity.

Following transduction with Adv-hHGF-hIlL-1Ra, islets were incubated with a
cocktail of cytokines, such as IL-1β (10ng/ml), TNF-α (10ng/ml) and INF-γ (50ng/ml).
Non-transduced islets with and without cytokine treatment were used as controls. Blank
media was also used as negative controls. Caspase-3 activity was determined at day 3
post-transduction by measuring the amount of caspase-3 present in the lysate of islets
after cell lysis using a Caspase-Glo 3/7 luciferase assay. Results are expressed as the
mean±S.D. of n=4. *p<0.05 and **p<0.02, compared to non-transduced islets with
cytokine treatment. NT, non-transduced islets without cytokine treatment.
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compared to that of non-traduced islets incubated with the cytokines. Since the islets
transduced at 2000 MOI showed much higher level of caspase-3 activity compared to that
of 1000 MOI transduced islets, we decided to transduce islets at 1000 MOI for in vivo
testing. The inability of Ad5 vectors to be integrated into the host genome is another
attribute of the Ad5 vectors that make them an attractive vector for transgene expression.
Also the Ad5 vectors lacking the E1 and E3 genes render them to produce less immune
response.170-172 The viral proteins synthesized will be minimal. However, a major concern
in the use of adenoviral vectors is safety. Therefore, the vector associated immune
response will be minimal. This is a very significant factor that needs to be thoroughly
addressed before it can be used in a clinical setting. Although the adenoviral vectors are
replication deficient, there are reports in the literature suggesting the immune response
these vectors could elicit following their administration.85,172,173 We have seen that at
higher doses 2000 MOI there was increase in caspase-3 activity in the islets transduced
by the Adv indicating that higher doses of the Adv can be detrimental to the survival of
islets following transplantation. This might be due to increase in vector backbone
resulting in eliciting immune response. Also, the viral proteins can elicit an immune
response. Therefore, we decided to use 1000 MOI of Adv concentration in all the studies.
We also determined the effect of Adv-hHGF-hIL-1Ra transduction on the levels of Bcl-2
(anti-apoptotic) and Bax (pro-apoptotic) by Western blot analysis. As shown in Figure
3-6, there was significant increase in Bcl-2 level, but decrease in Bax level.
3.3.5.

Islet Survival and Function after Transplantation

The effect of hHGF and hIL-1Ra gene expression on the islet survival and function
post-transplantation of 1000 islets transduced with Adv-hHGF-hIL-1Ra at 1000 MOI
under the kidney capsules of NOD-SCID mice was determined in terms of blood glucose,
human insulin, and C-peptide levels. Following transplantation, blood glucose level
decreased to around 200mg/dl for both the un-transduced control and Adv-hHGF- hIL1Ra-transduced islet transplanted mice. However, the mice transplanted with untransduced islets showed gradual increase in the blood glucose level reaching to
300mg/dl at day 28 post-transplantation. In contrast, no increase blood glucose level was
seen in case of the mice transplanted with Adv-hHGF-hIL-1Ra-transduced islets even at
28 day post-transplantation (Figure 3-7). After removal of the kidney containing islets
from some mice, blood glucose levels immediately returned to pre-transplant diabetic
levels (>500mg/dL), confirming that the transplant was responsible for reducing the
blood glucose (Figure 3-7).To further define the function of the transplanted islets,
glucose tolerance tests were performed at day 27 post-transplantation from the same
mice.
After intraperitoneal glucose injection, blood glucose values were significantly lower
in mice transplanted with Adv-hHGF-hIL-1Ra-transduced islets than in mice transplanted
with uninfected islets (Figure 3-8). These results collectively indicate that at 4 weeks
after transplantation of an equivalent mass of islets, Adv-hHGF-hIL-1Ra-transduced
islets lead to superior glucose control and to tolerance as compared with control islets.
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Figure 3-6

Effect of Adv-hHGF-hIL-1Ra on Bcl-2 and Bax protein levels.

Following transduction with Adv-hHGF-hIlL-1Ra, islets were incubated with a
cocktail of cytokines, such as IL-1β (10ng/ml), TNF-α (10ng/ml) and INF-γ (50ng/ml).
Non-transduced islets with and without cytokine treatment were used as controls. Bcl-2
and Bax was determined at day 3 post-transduction by Western blot analysis. Lane 1,
non-transduced islets; lane 2, non-transduced islets with cytokine treatment; lane 3, islets
transduced with Adv-hHGF-hIL-1Ra at 500 MOI with cytokine treatment; and lane 4,
islets transduced with Adv-hHGF-hIL-1Ra at 1000 MOI with cytokine treatment.
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Figure 3-7

Transplantation of Adv-hHGF-hIL-1Ra transduced islets.

Following transduction with Adv-hHGF-hIL-1Ra at 1000 MOI, 1000 islets were
transplanted under the kidney capsule of streptozotocin-induced diabetic NOD-SCID
mice. The mice transplanted with un-transduced islets were used as controls. The
nonfasting glucose levels were measured in each animal up to 28 days posttransplantation using a One Touch Ultra Glucometer (LifeScan, Inc.).
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Figure 3-8

Intraperitoneal Glucose Tolerance Test.

Glucose tolerance in streptozotocin-induced NOD-SCID mice transplanted with
uninfected or Adv-hHGF-hIL-1Ra transduced islets. At day 27 after the transplant, mice
were fasted overnight and then injected intraperitoneally with glucose (2g/kg of body
weight). Blood glucose levels were measured from the snipped tail at the time points
indicated with a glucometer. Results are the mean±S.D. of n=4. *P<0.05 compared with
control using ANOVA.
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Just before the removal of kidney containing islets, blood was collected for measuring
the serum insulin and C-peptide levels. As shown in Figure 3-9A and B, serum levels of
insulin and c-peptide were significantly higher in mice transplanted with Adv-hHGF-hIL1Ra transduced islets compared to un-transduced islet transplanted mouse groups,
indicating better islet engraftment and function. These results suggest that compared to
non-treated islets, co-expression of hHGF and hIL-1Ra sustained the low glucose level of
mice for prolonged period, and increased the levels of serum insulin and c-peptide.
3.3.6.

Immunohistochemistry

To determine whether hHGF gene expression after transduction with Adv-hVEGFhIL-1Ra will promote angiogenesis by human islets, we isolated the kidney bearing AdvhHGF-hIL-1Ra transduced islets at 28 days post-transplantation into diabetic NOD-SCID
mice for sectioning and staining with polyclonal rabbit hHGF and von Willebrand Factor
(hvWF) antibodies. Staining with anti-human insulin and untransduced islet sections
were used as the controls. The positive staining of hHGF was higher in the transduced
islets compared to un-transduced islets (Figure 3-10), suggesting efficient hHGF gene
expression after transduction with Adv-hHGF-hIL-1Ra. The positive staining of vWF
factor was more evident in Adv-hHGF-hIL-1Ra transduced islets, which is an indicator
for endothelial cells. Morphometric analysis revealed that Adv-hHGF-hIL-1Ra
transduced islet grafts exhibited higher hHGF and vWF-immunostaining intensity than
control islet grafts, with relative intensities of 1.70 vs. 1 for hHGF and 1.50 vs. 1 for
hvWF respectively.
To correlate the degree of islet revascularization with the islet mass in the kidney
capsule, we also stained for human insulin. Adv-hHGF-hIL-1Ra transduced islets (Figure
3-10A) displayed significantly higher levels of insulin content than control islet groups
(Figure 3-10D), with relative intensity of 1.7 vs. 1. This quantitative difference in insulin
content in the kidney capsule between Adv-hHGF-hIL-1Ra transduced and control islet
groups of diabetic recipient mice correlated well with their serum insulin and c-peptide
profiles (Figure 3-9). The positive staining for human insulin also confirmed the
functionality of islets. These results indicate the beneficial effect of Adv-hHGF-hIL-1Ra
for the islet survival and function post-transplantation.
3.4.

Discussion

Isolation and purification of islets are known to disrupt their microvasculature,
leading to hypoxia and apoptosis upon transplantation.133 HGF has been shown to
increase -cell proliferation vitro and ameliorate hyperglycemia in streptozotocininduced diabetic mice transplanted with murine islet transplantation.164,165,174
Islet injury stimulates resident macrophages and infiltrating leukocytes to produce
cytotoxic cytokines like IL-1β, TNF-α and IFN-γ. Among these inflammatory cytokines,
IL-1β is the key mediator of β cell destruction. Administration of recombinant IL-1Ra
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A

Figure 3-9

B

Serum insulin and c-peptide ELISA.

Following ex vivo transduction with Adv-hHGF-hIL-1Ra at 1000 MOI, 1000 islets
were transplanted under the kidney capsule of streptozotocin-induced diabetic NODSCID mice. The mice transplanted with un-transduced islets were used as controls. At
day 28 post-transplantation, the mice were sacrificed and blood was collected to measure
A) serum insulin and B) C-peptide by ELISA. Results are expressed as the mean±S.D.
(n=4) *p<0.05.
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Figure 3-10

Immunohistochemical staining of islet bearing kidney sections.

Immunohistochemical staining of islet bearing kidney sections at 28 days posttransplantation of human islets transduced with Adv-hHGF-hIL-1Ra at 1000 MOI.
Rabbit polyclonal anti-human HGF and hvW were used for detecting hHGF and
endothelial cells. A) Insulin, B) hvW and C) hHGF staining for Adv-hHGF-hIL-1Ratransduced islets; and D) insulin, E) hvW and F) hHGF staining for the control islets.
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protein has been shown to prevent islet dysfunction upon transplantation.151 Ex vivo
transduction of human islets with Adv-hIL-1Ra has been reported to prevent IL-1β
induced β cell impairment and activation of islet cell apoptosis.150 On the other hand,
HGF is known to induce angiogenesis, regenerate β-cells and protect islets from
apoptosis. Therefore, the objective of this study was to construct and characterize a
bipartite Adv vector, Adv-hHGF-hIL-1Ra, for enhancing the performance of human islet
grafts and correction of hyperglycemia upon transplantation under the kidney capsules of
STZ-induced diabetic NOD-SCID mice.
Apoptosis begins during the islet isolation process, peaks 2-3 days post
transplantation, and continues for approximately 7~14 days until what remains of the
graft has stabilized and become vascularized. Therefore, the use of replication deficient
Adv vectors promotes islet engraftment during the first week may be all that is necessary.
The lack of integration is an advantage as well, since it will not allow induction of several
key cell genes. The viral dose delivered to the patient by ex vivo gene therapy would be
small reducing concerns regarding anaphylaxis. Finally, hHGF and hIL-1Ra coexpression will suppress immune reaction, leading to attenuation of host allergic
reactions. Therefore, we decided to use ∆E1 and ∆E3 Adv vector because our goal was to
achieve transient gene expression, while avoiding other potential side effects and in vivo
virus replication. Since prolonged incubation with Adv vectors may induce apoptosis and
loss of endothelial cells; we decided not to co-culture the islets beyond 12h, we
determined HGF and hIL-1Ra gene expression at protein and mRNA levels. The protein
and mRNA levels of HGF and hIL-1Ra increased with increase in MOI (Figures 3-2 and
3-3), indicating the Adv vector is indeed expressing these two genes as desired. However,
these results cannot be directly correlated, since we used different primers for different
genes and thus we can only compare our real time RT-PCR results in relative to the house
keeping genes.
Apoptosis is a major pathway through which islets undergo cell death and has been
considered as a major factor for primary graft non-function.175 To mimic the in vivo
situation of the cytokine mediated insults, we incubated islets with a cocktail of
inflammatory cytokines such as IL-1β, TNF-α and IFN-γ. Caspase-3 is a converging
point of apoptosis for intrinsic and extrinsic pathways and caspase-6 and 7 are generated
from caspase-3. There was gradual increase in caspase-3 with increase in Adv-hHGFhIL-1Ra in the presence of these cytokines, but caspase-3 levels were much lower
compared to the un-transduced islets (Figure 3-5). The levels of caspase-3 at 500 and
1000 MOI was low, suggesting these Adv vectors are fairly safe at these tested doses.
Bcl-2 family of intracellular proteins plays an important role in regulation of cytochrome
C release into the cytosol and caspase activation. Anti-apoptotic members, such as Bcl-2,
Bcl-XL and Bcl-w are critical for cell survival, whereas pro-apoptotic members, such as
Bax, Bad and Bak among others promote apoptosis.176 Heterodimerization of Bcl-2 with
Bax or Bak modulates apoptosis, and the ratio of Bcl-2 to Bax or Bak determines survival
or death following an apoptotic stimulus. Transduction of islets with Adv-hHGF-hIL-1Ra
greatly enhanced the level of Bcl-2 protein while inhibited Bax protein level (Figure 3-6).
This result further demonstrates the protective effect of hHGF and hIL-1Ra co-expression
since Bcl-2 has been shown to inhibit cytochrome C release and protect against oxidative
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stress-induced apoptosis,177 indicating the usefulness of this vector in protecting islets
from apoptosis following transplantation.
Effect of Adv-hHGF-hIL-1Ra transduction on improvement in the survival and
function of islets post-transplantation was determined in streptozotocin-induced diabetic
NOD-SCID mice. We observed a reduction in blood glucose levels of mice transplanted
with Adv-HGF-hIL-1Ra transduced islets than that observed with un-transduced islets,
especially after 5 days post-transplantation, but increase in blood glucose levels for the
mice transplanted with un-transduced islets (Figure 3-6). This decrease in blood glucose
levels by Adv-hHGF-hIL-1Ra-transduced mice correlated with the higher amount of
serum insulin and C-peptide secreted by the islets at day 28 post-transplantation (Figure
3-9A and B). Our results are in good agreement with Lopez-Talavera et al.,146 who
observed glycemic control in Adv-HGF-transduced islet transplanted rats superior to the
tat observed in diabetic control rats. Revascularization of islet grafts after transplantation
is an important process that influences the long-term survival and function of the grafts.
Endothelial cells reside within isolated islets and potentially participate in the
revascularization process. Immunohistochemical staining in the islet bearing kidney
sections at day 28 after transplantation was positive for human insulin, hHGF and vWF
(Figure 3-10). Positive staining for insulin, which stains pancreatic β-cells corroborates
the serum insulin data (Figure 3-9A) and confirms that islets are indeed functional after
transplantation, which is in good agreement with the contemporary literature. vWF is
human endothelial cell marker. Therefore, relatively stronger positive staining for hHGF
and vWF antigens by the Adv-hHGF-hIL-1Ra transduced islet bearing kidney section
groups indicates that blood vessel formation in the transplanted islets was relatively more
efficient when islets were transduced with Adv-hHGF-hIL-1Ra prior to transplantation.
These results indicate that HGF and hIL-1Ra co-expression is likely to reduce the
islet mass required to achieve normoglycemia. Although we did not examine the
apoptosis in graft islet cells, our in vitro data clearly indicated that transduction of AdvHGF-hIL-1Ra led to significant reduction of caspase-3 activity, which is the indicator of
apoptosis.
We have tested two different adenoviral vectors Adv-hVEGF-hIL-1Ra and AdvhHGF-hIL-1Ra by transducing them into human islets and studying their survival and
function following transplantation in NOD-SCID mice. Both VEGF and HGF are
angiogenic growth factors. However, we replaced VEGF with HGF as HGF not only
promotes revascularization, but also can protect the islets from apoptosis. It can also
promote the proliferation of β-cells and also has shown to decrease the islet mass needed
for achieving normoglycemia. In our studies, we have seen that the islets transduced with
Adv-hHGF-hIL-1Ra maintained normoglycemia in diabetic NOD-SCID mice for longer
period compared to islets transduced with Adv-hVEGF-hIL-1Ra. Also, we have seen the
toxicity of adenoviral vectors at higher doses thereby needing to decrease the viral dose
for transducing islets prior to transplantation. Considering all these factors, it can be
clearly said that Adv-hHGF-hIL-1Ra is more apt for transducing the human islets to
improve their survival and function following transplantation. Although, further studies
are warranted to study the immunogenicity of the adenoviral vectors, their effect
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following transplantation of Adv transduced islets in the hepatic portal vein mimicking
the human setting to clearly say about the usefulness of these vectors in clinical setting.
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CHAPTER 4. TRIPLEX FORMING OLIGONUCLEOTIDES AGAINST TYPE
ΑLPHA 1(I) COLLAGEN ATTENUATES LIVER FIBROSIS INDUCED BY BILE
DUCT LIGATION
4.1.

Introduction

Liver fibrosis results from chronic damage to the liver in conjunction with the
accumulation of extracellular matrix (ECM) proteins, which is a characteristic of most
chronic liver diseases.68 The main causes of liver fibrosis in industrialized countries
include chronic hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic
steatohepatitis (NASH). Such chronic diseases lead to scarring in the liver that, with
increasing severity, prevents effective liver regeneration and maintenance of liver
function.178 Liver fibrosis is associated with major alterations in both the quantity and
composition of ECM. The accumulation of ECM proteins distorts the hepatic architecture
by forming a fibrous scar, and the subsequent development of nodules of regenerating
hepatocytes defines cirrhosis.179
Type I collagen, the major component of the extracellular matrix in the fibrotic liver,
is a heterotrimer composed of 2 1 chains and 1 2 chain. These chains are encoded by 2
distinct genes, COLlAl and COLlA2, respectively. Hepatic stellate cells (HSCs; also
known as vitamin A-storing cells, fat-storing cells, Ito cells, and lipocytes) residing in the
perisinusoidal space of Disse in the liver, are the main producers of type α1(I) collagen
and other components of extracellular matrix in both normal and fibrotic livers.180,181
Following chronic injury, cytokines such as transforming growth factor β (TGF-) and
protein kinase signaling pathways mediate a complex interplay among different hepatic
cells.182-184 Under the influence of these signals, HSCs activate or transdifferentiate into
myofibroblast-like cells, acquiring contractile, proinflammatory, and fibrogenic
properties resulting in increased synthesis of types I and III fibrillar collagen.185,186
In contrast to the traditional view that cirrhosis is an irreversible disease, recent
evidence indicates that even advanced fibrosis is reversible.187,188 Preclinical studies have
reported a scientific rationale and experimental evidence supporting the use of many
potential therapies for fibrosis. Such therapies have been targeted to any of several
different biological targets (e.g., inhibition of collagen synthesis, interruption of matrix
deposition, stimulation of matrix degradation, modulation of stellate cell activation, or
induction of HSC death). Triplex-forming oligonucleotides (TFOs) constitute an
interesting DNA sequence-specific tool that can be used to target cleaving or crosslinking agents, transcription factors or nucleases to a chosen site on the DNA. TFOs have
proved effective in altering gene expression by interfering with the binding of
transcription factors.189,190 Because liver fibrosis is due to the overproduction of Type I
collagen by liver fibrogenic cells, targeted inhibition of transcription of type α1(I)
collagen gene is expected to prevent fibrosis. Recently, we showed that antiparallel
phosphorothioate (APS) TFOs specific for α1(1) collagen form triplexes efficiently and
inhibit transcription in cultured immortalized rat hepatic stellate cells (HSC-T6) in
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vitro.191 These results suggest that targeting collagen transcription may theoretically
attenuate fibrosis in livers undergoing tissue remodeling.
In the current study, we studied the antifibrotic effects of TFOs in rats undergoing
common bile duct ligation (CBDL). TFO administration in CBDL rats resulted in
decreased liver injury, inflammation, and fibrosis. At the cellular level, TFO induced
similar effects in primary rat HSCs. This evidence indicates that the prevention of fibrosis
by anti-collagen TFO treatment could preserve organ function and be therapeutically
useful. Our data may suggest that anticollagen TFOs could be effective in future gene
therapy for fibrosis in vital organs.
4.2.
4.2.1.

Materials and Methods
Materials

TFO, which was a 25-mer antiparallel fully phosphorothioate ODN (3’GAGGGGGGAGGAGGGAAAGGAAGGG-5’) targeting rat α1(I) collagen gene
promoter was synthesized by Invitrogen (Carlsbad, CA). Bovine serum albumin (BSA)
(fraction V, purity>98%) was purchased from USB Corporation (Cleveland, OH). SYBR
Green-1 dye universal master mix and MultiScribe reverse transcriptase were purchased
from Applied Biosystems, Inc. (Foster City, CA). Tumor necrosis factor (TNF)-α ELISA
kits were purchased from eBioscience, Inc. (San Diego, CA). RNA extraction kit was
procured from Promega (Madison, WI). Immobilon polyvinylidene fluoride (PVDF)
membrane was purchased from Millipore (Billerica, MA). Rabbit antirat TGF-β1 and βactin primary antibodies and horseradish peroxidase-conjugated goat antirabbit secondary
antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Chemiluminescence (ECL) detection kit was purchased from GE Healthcare Life
Sciences (Pittsburgh, PA). Serum alanine transaminase and aspartate transaminase kits
were purchased from ID Labs, Inc (London, Canada). Citric acid and sodium citrate were
procured from Curtin Matheson Scientific, Inc (Houston, TX). Sodium hydroxide was
purchased from Fisher Scientific, (Fair Lawn, NJ). Hydroxyproline, Chloramine-T, 3, 3'diaminobenzidine (DAB) and goat serum were purchased from Sigma-Aldrich (St. Louis,
MO).
4.2.2.

Animals and Experimental Design

Male Sprague–Dawley rats weighing 250–280g were maintained under conditions as
per the NIH (http://grants1.nih.gov/grants/olaw/references/phspol.htm) and institutional
animal care and use Committee using the approved protocol. All animals were housed in
microisolator cages in virus-free facilities and fed laboratory chow ad libitum. CBDL or
sham operation was performed as described previously.192-194 After a midline laparotomy,
liver lobes were retracted upwards and the intestines were reflected to the right to expose
the common bile duct (CBD). The CBD was then isolated by careful blunt dissection,

69

doubly ligated with 4-0 silk and transected between the two ligations. The sham operation
was performed similarly, with the exception of ligating and transecting the bile duct.
Liver was then replaced into the abdominal cavity making sure there were no twists in the
vascular pedicles of its lobes. The abdomen was closed with 4-0 silk running suture. Rats
were injected with TFO at 8mg/kg per dose twice a week for 4 weeks via the tail vein.
Sham operated rats and CBDL control rats were injected with an equal volume of saline.
Animals were sacrificed after 7 weeks. Blood and liver tissue were collected for
biochemical, RNA, histological and immunohistochemical studies.
4.2.3.

Cell Culture

Immortalized rat hepatic stellate cells (HSC-T6) were a kind gift by Dr. Scott
Friedman (Mount Sinai School of Medicine, New York). HSC-T6 cells at a density of
1X106 cells were seeded on uncoated plastic tissue culture 6-well plates and cultured in
Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL, Grand Island, NY) containing
10% of fetal bovine serum (FBS) until 50% confluence was achieved. The growth
medium was replaced with a pre-warmed serum-free DMEM. TFO was mixed with
lipofectamine 2000 according to the manufacture’s protocol and then used for
transfection. Scrambled TFO was used as control.
4.2.4.

Serum Transaminase Levels

Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) were used as markers of liver injury. ALT and AST concentrations were measured
using IDTox™ Alanine transaminase color endpoint assay kit and IDTox™ Aspartate
transaminase enzyme assay kit (ID LabsTM Inc, London, ON, Canada) according to the
manufacturer’s instructions and absorbance was measured using a spectrophotometer.
4.2.5.

Hydroxyproline Assay

Hydroxyproline content was quantified colorimetrically from 30mg of liver tissue as
previously described.195 Briefly, fresh liver tissue was collected and weighed at the time
of sacrificing the animals. The tissue was then hydrolyzed with 6N HCl and then heated
in an oven at 110°C for 18h. The tissue was incubated in a vacuum desiccator overnight
until the HCl was completely dried. Citrate buffer was added to dilute the samples. Then,
Chloramine-T reagent was added to the samples and allowed to react for 20 min at room
temperature. Following this, fresh Ehrlich’s reagent was prepared and added to each
sample. Samples were then placed in a warm water bath (60°C) and allowed to react for
15 min. Samples were then cooled to room temperature and absorbance was read at
550nm for each sample and a standard control. The results were expressed as micrograms
of hydroxyproline per grams of liver. Hydroxyproline standard curve was also prepared
using variable concentrations of it and plotting the standard curve after measuring the
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absorbance at 560nm. Hydroxyproline levels correspond to the total amount of collagen
present.
4.2.6.

ELISA for Tumor Necrosis Factor-

Cell culture supernatant or serum was used to determine the levels of TNF- using an
ELISA kit according to the manufacturer's specifications (eBiosciences, San Diego, CA).
For in vitro studies, rat HSC-T6 cells were cultured as described above. Medium was
removed and cells incubated in serum-free medium for 24h. Supernatants were collected
and stored at-80°C until analysis. For in vivo studies, blood was collected immediately
after euthanasia and centrifuged at 10,000 rpm for 7 min at room temperature to separate
the serum. Serum was at-80°C for future use. ELISA data were then presented as the
percentage (%) of the control for in vitro studies or picograms per milliliter of serum for
in vivo studies.
4.2.7.

Myeloperoxidase (MPO) Activity Assay

The presence of MPO, an enzyme specific for neutrophils, was used as an index of
liver neutrophil accumulation. Briefly, the frozen tissue was thawed and placed in 4 ml
iced 0.5% hexadecyltrimethylammonium bromide and 50 mmol potassium phosphate
buffer solution with the pH adjusted to 5. Each sample was homogenized for 30 s and
centrifuged at 15,000 rpm for 15 min at 4°C. Supernatants were then mixed with
hydrogen peroxide–sodium acetate and tetramethyl benzidine solutions. The change in
absorbance was measured spectrophotometrically at 460nm. One unit of MPO activity
was defined as the quantity of enzyme degrading 1 mol peroxide per minute at 25°C per
gram of tissue.
4.2.8.

Real Time Polymerase Chain Reaction

To determine Type I collagen, alpha smooth muscle actin (α-SMA), TGF-β1, and
tissue inhibitor of metalloproteinase 1 (TIMP-1) gene expression in rat liver, total liver
RNA was extracted using RNeasy extraction kit (Qiagen, Valencia, CA). RNA
concentration and purity was measured and confirmed using Nanodrop (Thermo
Scientific, Wilmington, DE). Total RNA (385ng) was reverse transcribed to cDNA
templates using MultiScribe reverse transcriptase and random hexamers by incubation at
25°C for 10 min, followed by reverse transcription at 48°C for 30 min and enzyme
inactivation at 95°C for 5 min. In all 100ng of cDNA was amplified by real time PCR
using SYBR Green dye universal master mix on an LightCycler®480 (LC 480) (Applied
Biosystems, Inc., Foster City, CA) using the primers (Table 4-1) for Type I collagen
(NCBI Accession#NM_053304.1), α-SMA (NCBI Accession#NM_031004.2), TGFβ1(NCBI Accession#NM_021578.2), TIMP-1(NCBI Accession#NM_053819.1). The
PCR products were subjected to a melting curve analysis and crossing point (Cp) was
used for calculating the relative amount of mRNA compared to the house keeping gene,
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Table 4-1

Gene

Primers for real time PCR.

Forward Primer (5'-3')

Reverse Primer (5'-3')

α1(I)
collagen TGGTCCCAAAGGTTCTCCTGGT

TTAGGTCCAGGGAATCCCATCACA

α-SMA ACAACGTGCCTATCTATGAGGGCT AGCGACATAGCACAGCTTCTCCTT
TGF-β1 CATCCATGACATGAACCGACCCTT ACAGAAGTTGGCATGGTAGCCCTT
TIMP-1 CCTCTGGCATCCTCTTGTTGCTAT CATTTCCCACAGCGTCGAATCCTT
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hypoxanthinephophoribosyltransferase (HPRT), and then scaled relative to controls,
where control samples were set at a value of 1. Thus, results for all experimental samples
were graphed as relative expression compared with the control. Melting curve analysis
was also done to check the amplification specificity.
4.2.9.

Histological Staining

Formalin-fixed liver specimens from the TFO treated, BDL and Sham operated rats
were dehydrated in alcohols, incubated in xylene, and embedded in paraffin. Fivemicron-thick tissue sections were cut and stained with either hematoxylin-eosin for
general histology or Masson’s trichrome for collagen staining, according to
manufacturer's protocols.
4.2.10. Immunofluorescent Staining
Immunofluorescent staining was performed on snap frozen liver tissue. Briefly, 5m
cryosections were cut on lysine coated slides and fixed in 95% cold ethanol. Slides were
air dried and stored at -80ºC till further use. The sections were blocked with 10% goat
serum with 1% BSA in PBS for 2h at room temperature. Cryosections then incubated
with the following primary antibodies overnight at 4C: anti rabbit α- SMA, anti rabbit
TGF-β, and anti-mouse cytoketain-19. The following secondary antibodies were used,
anti-rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 594 and anti-rabbit Alexa Fluor 594.
Nuclear staining was performed using 4', 6-diamidino-2-phenylindole (DAPI).
Immunofluorescence was visualized on a Zeiss Apoplan Microscopy system.
4.2.11. Statistical Analysis
Data are expressed as the mean±standard deviation (SD). Difference between any two
groups was determined by ANOVA and t-test. P<0.05 was considered statistically
significant.
4.3.
4.3.1.

Results
TFO Downregulates Type 1 (I) α-Collagen In Vitro

HSCs were cultutred and transfected with 1µg of TFO. mRNA analysis showed a
drastic decrease in the expression of type 1 (I) α-Collagen in the HSCs transfected with
TFO inhibiting type 1 (I) α-Collagen compared to that of scrambled TFO and
untransfected HSCs (Figure 4-1).

73

Figure 4-1

TFO down regulated type 1 (I) α-collagen in HSCs.
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4.3.2.
Vitro

TFO Downregulates Profibrogenic and Proinflammatory Cytokines in HSCs In

TGF-β1 and TIMP-1 are the two major profibrogenic cytokines implicated in the
development of liver fibrosis.196-198 As shown in Figure 4-2A, transfection of HSC-T6
cells with 1g of TFO complexed with Lipofectamine significantly attenuated expression
of TIMP 1 and TGF-β1 mRNAs on real time PCR. Similarly, TFO significantly
decreased proinflammatory cytokine TNF-α concentration in cultured medium as
measured by ELISA (Figure 4-2B).
4.3.3.

TFO Attenuates Chronic Liver Injury in CBDL Rats

To examine the effect of TFO on liver fibrosis, the common bile ducts of rats were
ligated and at 3 weeks post CBDL, three rat livers were isolated to confirm liver fibrosis
by evaluating i) macroscopically, ii) hydroxyproline assay and Masson’s trichrome
staining (data not shown). Then, TFO was injected intravenously twice a week at a dose
of 8mg/kg for 4 consecutive weeks and the degree of liver fibrosis was assessed by using
three independent methods: collagen quantitation by measuring hydroxyproline content,
Col 1A2 mRNA level in the liver samples and histological analysis by hematoxylin and
eosin histological staining as well as Masson’s trichrome staining. Hydroxyproline is a
quantitative measure of collagen deposition and fibrosis.199 As expected, there was
significant increase in hydroxyproline content in the liver following CBDL, indicating
that the liver fibrosis model was successfully established. TFO treatment reduced
hydroxyproline content in the fibrotic liver, which was similar to that of the normal rats
(Figure 4-3).
To determine whether the decrease in hydroxyproline content in the liver of TFO
treated CBDL rats was due to the transcription inhibition of α1(1) collagen, we
determined collagen mRNA levels by real time PCR. The levels of α1(I) collagen mRNA
(corrected by the steady-state levels of HPRT mRNA) were decreased in the liver of TFO
treated CBDL rats.
4.3.4.

Histopathological Alterations

Liver architecture of fibrotic livers with or without TFO treatment was determined by
hematoxylin and eosin histological staining. As shown in Figure 4-4, there was
significant number of bile infarcts noticed in the BDL liver sections. TFO treatment
showed significant reduction in the bile infarcts. Figure 4-5 shows Masson’s trichrome
staining of the liver sections of the control, CBDL and TFO-treated rat livers. In the
control rats which were exposed to saline only, deposition of collagen was found
surrounding the central veins and enclosing portal triads representing the collagen
distribution of healthy livers. CBDL rats being treated with saline over 4 weeks displayed
a periportal fibrosis characterized by portal-portal septa surrounding the lobules. Collagen
deposition was extensive in the peribiliary and interstitial tissue. There were also

75

A

Figure 4-2

B

In vitro effect of TFO on HSC cells.

A) Effect on TIMP1 and TGF-β1 expression after transfection of HSC-T6 cells with
TFO after complex formation with lipofectamine 2000. At 72h post-transfection, cells
were harvested, total RNA was extracted, and TIMP1 and TGF-β1 expression was
determined at mRNA levels using real time PCR. B) TNF-β concentration in cultured
medium was measured by enzyme-linked immunosorbent assay (ELISA). Data are
expressed as the mean±standard deviation (SD).
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Figure 4-3

Hydroxyproline assay.

Total tissue hydroxyproline content was determined by biochemical assay at 7 weeks
after BDL. Data are expressed as micrograms of hydroxyproline per milligram of tissue.
Results are expressed as the mean±S.D. *P<0.05 compared with control using ANOVA
and t-test. TFO treatment reduces hepatic hydroxyproline content.

77

Figure 4-4

Hematoxylin and Eosin staining of livers sections.

TFO gene therapy attenuates liver fibrosis induced by BDL. Hematoxylin and Eosin
staining staining of liver tissue sections from control, BDL and TFO–treated rats at 7
weeks after BDL.
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Figure 4-5

Masson’s Trichrome staining for collagen.

TFO gene therapy attenuates liver fibrosis induced by BDL. Masson’s trichrome
staining of liver tissue sections from control, BDL and TFO–treated rats at 7 weeks after
BDL. Significantly less hepatic collagen staining was observed in TFO-treated rats.

79

confluent areas of necrotic hepatocytes in the collagenized zones. TFO administration,
however, resulted in a marked reduction in the fibrotic stage indicated by decreasing
portal and periportal accumulation of collagen and essentially no collagen accumulation
was found in liver interstitium (Figure 4-5). Also, there was further reduction in
branching of collagen in the liver sections of TFO treated rats compared to that of
common bile duct ligated rats.
A computer-aided morphometric analysis revealed that the intensity of collagen
staining in the liver sections at 7 weeks after CBDL was reduced by 60% after TFO
treatment, when compared with the saline treated CBDL rats.
4.3.5.

Effect of TFO on Liver Functions and Serum Fibrotic Markers

ALT is a cytosolic enzyme, primarily present in the liver. An increase in plasma ALT
indicates liver damage more specifically than AST, which is a mitochondrial enzyme
present in large quantities in the heart, liver, skeletal muscle, and kidney and in part
indicates liver injury. At 7 weeks post CBDL, serum AST and ALT levels as determined
by colorimetric assay were significantly higher in BDL animals with no TFO treatment
compared with the CBDL rats treated with TFO (Figure 4-6).
4.3.6.

TFO Attenuates In Vivo Myofibroblast Activation

To provide further evidence of the anti-fibrotic properties of TFO in CBDL rats, we
used real time RT-PCR to determine the effects of this compound on hepatic α-SMA
protein expression, a well-established marker of HSC activation during liver
fibrogenesis.200 Compared with sham controls, α-SMA mRNA expression in the CBDL
liver at 7 weeks was markedly increased, suggesting activation of the hepatic
myofibroblasts following CBDL-induced injury. However, the induction of α-SMA
mRNA in the fibrotic liver was largely blocked by intravenous administration of TFO
twice a week for four consecutive weeks at 3 weeks after CBDL (Figure 4-7). We next
examined hepatic myofibroblast activation after CBDL by using immunofluorescence
staining. In the normal rat liver, α-SMA was exclusively and strongly expressed in vessel
walls (portal vessels and centrilobular veins). The staining for α-SMA was dramatically
increased in CBDL liver forming whorls of layers (onion skinning) around the
proliferated bile ductules. In addition to the peribiliary region in which α-SMA positive
cells were observed, strong α-SMA staining was also found in enlarged and/or
proliferated biliary epithelia (Figure 4-8). However, α-SMA staining was fairly week in
the fibrotic liver after intravenous administration of TFO twice a week for four
consecutive weeks at 3 weeks after CBDL (Figure 4-8).
To confirm the epithelial origin of α-SMA-positive cells, we used double
immunofluorescence staining for biliary epithelial marker cytokeratin-19 (red) and αSMA (green). Figures 4-9 and 4-10 demonstrate clear colocalization of cytokeratin-19
and myofibroblast marker α-SMA in biliary epithelial cells at 7 weeks after CBDL.
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Figure 4-6

Serum ALT and AST assay.

Effect of TFO treatment on alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) content. ALT and AST levels were determined by colorimetric
assay at 7 weeks after CBDL in rats TFO treatment reduces hepatic ALT and AST
content compared to CBDL rats without any TFO treatment. Results are expressed as the
mean±S.D. *P<0.05 compared with control using ANOVA.
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Figure 4-7

Real time PCR analysis for α-SMA.

Reverse transcription-PCR showed an inhibitory effect of TFO on α-collagen
expression levels in BDL rats. The mRNA levels of α-collagen and α-SMA was
determined by reverse transcription-PCR 7 weeks after BDL. *P<0.05 compared with
control using ANOVA.
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Figure 4-8

Immunoflorescent staining for α-SMA.

Immunoflorescent staining for α-SMA in A) Control B) BDL and C) TFO treated
liver sections at 10X magnification respectively. Arrows indicate the positive staining for
α-SMA in and proliferated bile ductules.
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Figure 4-9

Double immunostaining for cytokeratin-19 and α-SMA.

Double immunostaining for cytokeratin-19 and α-SMA in A) Control B) BDL and C)
TFO treated liver sections. The arrows indicate the colocalization of cytokeratin-19 and
α-SMA indicating the phenomenon of epithelial-mesenchymal cell transition (EMT)
occurring in and around the peribiliary space.

84

Figure 4-10

Colocalization of Cytokeratin-19 and α-SMA.

Double immunostaining for cytokeratin-19 and α-SMA in A&B) BDL and C&D)
TFO treated liver sections. Merging of cytokeratin-19 and α-SMA is shown in C&F. All
the images are at 10X magnification.
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Exogenous TFO, however, prevented the coexpression of cytokeratin-19 and α-SMA in
biliary epithelium. These observations imply that biliary epithelial cells may undergo a
phenotypic transition into myofibroblasts under pathological conditions and that
exogenous TFO administration could protect the biliary epithelia by blocking this
phenotypic transition.
4.3.7. TFO Inhibits Neutrophil Infiltration by Downregulating Inflammatory
Cytokines
CBDL may cause hepatocyte apoptosis due to TNF-α upregulation and consequent
neutrophil infiltration. Therefore, we determined the amount of TNF-α secreted from the
livers of TFO treated and non-treated CBDL rats. There was only slight elevation in
TNF-α level in the non-treated BDL group indicating only minor inflammation following
the induction of liver fibrosis by bile duct ligation (Figure 4-11A). The level of
myeloperoxidase (MPO) which is a marker for neutrophil infiltration was less in the TFO
treated CBDL group compared to non-treated CBDL group, indicating that TFO
treatment can decrease neutrophilic infiltration by inhibiting the release of inflammatory
cytokine such as TNF-α (Figure 4-11B).
4.4.

Discussion

Fibrosis is characterized by an excessive production of ECM components, especially
Type I collagen, and if not controlled it can lead to organ dysfunction.201 Therefore,
inhibition of collagen synthesis should prevent fibrosis. Joseph et al., demonstrated that
antiparallel polypurine phosphorothioate oligonucleotides could form triplexes with the
C1 region of the α1(I) collagen gene promoter and inhibit transcription of α1(I) collagen
gene promoter activity in rat fibroblasts in culture.82 We determined triplex formation of
a psoralen modified TFO with α1(I) collagen gene in isolated nuclei and intact HSC-T6
cells, and demonstrated strong correlation between triplex formation and transcription
inhibition of TFOs.191 HSCs are the key fibrogenic cells and upon activation they convert
into myofibroblast- like cells, excrete excess ECM components, and overexpress TGF-β1
and α-SMA, which are markers for myofibroblasts and fibronectin, respectively.202
Therefore, in our previous studies, we isolated different liver cells after systemic
administration of TFO and demonstrated almost 40% of the total liver recovery was in
the HSCs.203 In the present study, we investigated the therapeutic effect of TFO on liver
fibrosis in rats induced by CBDL, which is a commonly used animal model.
The serum TNF-α levels were elevated following CBDL, and was noted to be lower
in the TFO treated group (Figure 4-11A). TNF-α is an important mediator of
hepatotoxicity and is upregulated in several animal models of chronic and acute liver
injury. Gabele et al., have studied the effect of CBDL on TNF- α knockout mice and
found them to be more resilient to the liver injury secondary to CBDL.204 They also
showed that TNF-α knockout mice had a significant decrease in expression of collagen,
α-SMA and TGF-β1 upon induction of fibrosis by BDL. Histopathological examination
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Figure 4-11

TNF-α ELISA and Myeloperoxidase assay.

A) Effect of in vivo TFO treatment on TNF-α. Rat serum was separated from the
plasma. Following separation, TNF-α in serum were measured by enzyme-linked
immunosorbent assay (ELISA). B) Myeloperoxidase (MPO) activity in the liver tissue of
CBDL sham and TFO treated Time (Min) ELISA). CBDL, groups. One unit of MPO
activity was defined as the amount of the MPO in 1 gram of liver tissue that could change
1 OD in absorbance at 460nm.
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of the liver tissue using Masson’s trichrome staining also revealed a decrease in staining
after treatment with TFO twice a week for 4 consecutive weeks at 3 weeks post CBDL
(Figure 4-5). In addition, the TFO treated group also showed less neutrophilic infiltration
compared to the BDL group suggesting the attenuation of liver fibrosis. The increase in
concentration of ALT and AST levels seen following BDL also showed a decreasing
trend after TFO treatment indicating reduction of hepatic inflammation. Xia et al., have
shown that mesenchymal cell transition (EMT) plays a vital role in the development of
liver fibrosis due to CBDL.205 TGF-1 has also been shown to induce EMT transition to
induce idiopathic pulmonary fibrosis.186 There have been reports, which suggest that the
cultured neonatal rat hepatocytes undergo EMT at specific conditions.206 It will not be
surprising if BECs undergo phenotypic transition to matrix–producing myofibroblasts
after CBDL. It has also been seen that there is a decrease in the hepatic myofibroblast
activation and biliary fibrosis when EMT was blocked by hepatocyte growth factor.205
TGF-β1 is also an important factor resulting in EMT resulting in fibrosis. There are
several reports in the literature which have showed that TGF-β1 can induce EMT
upregulation of Smad-interacting protein-1 (SIP1) and Snail.206-208 In the present study,
TGF-β1 levels were increased significantly following BDL as seen by Western blot.
Treatment with TFO showed a significant reduction in TGF-β1 levels. (data not shown)
These findings suggest that the transformed HSCs possibly secreted TGF-β1. This is also
consistent with the current idea that HSCs are transformed into myofibroblasts and
secrete TGF-β1, thus stimulating the production of ECM, and probably their
proliferation, through a paracrine/autocrine loop.
In the present study, we have shown that CBDL results in the transformation of
biliary epithelial cells (BECs) to α-SMA expressing myofibroblasts which migrate into
the periductal region through the impaired basement membrane. Most of BECs around
the bile duct in CBDL rats were found positive for α-SMA (Figure 4-8) corroborating the
fact that EMT may be the phenomenon behind the development of myofibroblasts. There
was also considerable co-localization of both α-SMA and Cytokeratin-19 in the
interstitium around the bile duct suggesting migration of newly formed myofibroblasts
(Figures 4-9 and 4-10).
TFO treatment can inhibit the transcription of Type I collagen and also decrease in αSMA levels in TFO treated group, suggesting that the inhibition of collagen can also lead
to down regulation of α-SMA levels. This helps in attenuating fibrosis induced by CBDL.
Furthermore, it also inhibits the EMT, thereby decreasing the development of
profibrogenic cells and inhibiting the accumulation of ECM. This study shows that a TFO
can have a beneficial effect on decreasing liver fibrosis and reversing progression of liver
injury. Further studies would be required to understand the exact mechanism by which
the TFO inhibits EMT.
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CHAPTER 5. SUMMARY
Transplantation therapy for diabetes is limited by the toxicity of immunosuppressive
drugs. However, even if toxicity can be minimized, there will still be a shortage of human
donor organs. Ex vivo transplantation of islets can be a viable alternative for treating
diabetes. Transplantation of islets is a viable therapy for treating Diabetes. However,
there are certain problems that need to be overcome. The major problems for islet
transplantation are lack of revascularization following transplantation and the nonfunction of islet grafts due to immune responses following transplantation. We used
adenoviral vectors encoding VEGF/HGF and IL-1Ra genes which can help in
revascularization of islets and protect the islets from immune mediated destruction.
We constructed Adenoviral vector encoding VEGF and IL-1Ra. Initially we
confirmed the expression of the genes, VEGF and IL-1Ra following transduction in
human islets. There was very high expression of these genes from the Adv transduced
islets compared to non-transduced islets. We further checked the functionality and
viability of islets following Adv transduction. The stimulation indices of Adv transduced
islets were similar to the non-transduced islets indication no detrimental effects from the
Adv. Following this, we studied the effect of IL-1Ra in protecting the islets from
apoptosis by incubating the Adv treated islets in a cytokine cocktail. The caspase-3 levels
were less compared to that of the islets with no Adv transduction. We then transplanted
islets transduced with the Adv-hVEGF-hIL-1Ra in the kidney capsules of NOD-SCID
diabetic mice. The islets transduced with Adv showed better metabolic control and
functionality and were able to lower the blood glucose levels for a long period of time
compared to mice transplanted with non-transduced islets or control vector Adv- Lacz.
There was also an increase in expression of insulin and c-peptide in mice transplanted
with Adv compared to mice transplanted with non-transduced islets.
Immunohistochemical staining of kidney sections revealed extensive staining for insulin
and human vonWillebrand factor (marker for endothelial cells) in Adv-hVEGF-hIL-1Ra
transduced islets. This shows that the bicistronic adenoviral vector indeed expressed the
genes VEGF and IL-1Ra and was able to decrease the blood glucose levels in the
Diabetic NOD-SCID mice.
We then decided to replace VEGF with HGF as HGF can not only promote
revascularization of islets, but also can further promote β- cell proliferation, function and
survival following transplantation. HGF gene therapy also showed reduction in minimum
islet transplant mass required for transplantation. Adenoviral-mediated gene transfer of
HGF has been shown to improve islet transplant outcomes. HGF is also known to inhibit
apoptosis. We constructed Adv-hHGF-hIL-1Ra and transduced them to human islets to
see the expression of HGF and IL-1Ra. There was dose and time dependent expression of
both the genes from the vector. The Adv vectors were relatively safe at lower dose of
around 1000 MOI with the stimulation index being similar to that of control nontransduced islets. Then we studied the effect of Adv in protecting the islets from
apoptosis. The islets transduced with Adv-hHGF-hIL-1Ra showed less expression of
caspase-3 compared to control indicating the effectiveness of Adv in protection from

89

apoptosis. Transplantation of islets transduced with Adv-hHGF-hIL-1Ra showed better
metabolic function and decreased the blood glucose levels for a longer time compared to
NOD-SCID mice transplanted with non-transduced islets. Immunohistochemical staining
of kidney sections showed extensive staining for insulin and hVw factor for Adv
transplanted islets compared to that of non-transplanted control. At the end of in vivo
study, intraperitoneal glucose tolerance test (IPGTT) was done to study the metabolic
function of transplanted islets. The mice transplanted with Adv transduced islets behave
well compared to those with non-transduced islets.
In summary bipartite Adenoviral vectors which are replication–deficient can be used
successfully for transducing islets for improving the islet transplantation outcomes. We
saw a decrease in blood glucose levels in NOD-SCID mice transplanted with Adv
transduced islets and further these islets were able to decrease the blood glucose levels
for a sustained period of time. Adv vectors were relatively safe at MOI up to 1000 and
showed efficient expression of VEGF, HGF and IL-1Ra corroborating the literature.
More studies reflecting the immune responses from these vectors need to be studied to
further confirm the beneficial effects of these vectors in islet transplantation. Further,
HGF thereapy can decrease the number of islets needed for transplantation, which is very
crirtical as there is an enormous shortage in islets required to attain euglycemia.
Liver fibrosis is a result of accumulation of fibrous, scar tissue in the liver. It usually
occurs due to the injury to liver cells (hepatocytes) by trauma, viral infection, excessive
alcohol consumption, toxins or other factors that lead to increase in activation of immune
system and resulting in the excessive accumulation of ECM. The hepatic stellate cells
(HSCs) get activated resulting in inflammation of hepatocytes causing excessive
accumulation of Type I collagen and ECM. It is often associated with high morbidity and
mortality and can lead to the need for a liver transplant. There has been no proper therapy
for liver fibrosis till now. Bile duct ligation is the most frequently used method in
developing fibrosis. We have evaluated the use of TFOs inhibiting Type I collagen in
attenuating fibrosis induced by bile duct ligation. BDL is a commonly used animal model
for inducing fibrosis in liver. Biliary fibrosis can be caused either due to biliary atresia or
primary sclerosing cholangitis. The injury to the bile duct by performing BDL may
trigger a chain of events resulting in the development of fibrosis.
We have shown that BDL results in the transformation of BECs to α-SMA expressing
myofibroblasts which apparently migrate into the periductal region through the impaired
basement membrane. Most of the BECs around the bile duct in BDL rats were found
positive for α-SMA corroborating the fact that EMT may be the phenomenon behind the
development of myofibroblasts. Further, colocalization of α-SMA and Cytokeratin-19 in
the BECs confirmed the phenotypic transition of BECs to mesenchymal cells. There was
considerable colocalization of both α-SMA and Cytokeratin-19 in the interstitium around
the bile duct signifying the migration of newly formed myofibroblasts. This phenomenon
was mitigated in the animals treated with TFO inhibiting Type I collagen. TGF-β1 can
be an important factor resulting in biliary EMT of hepatocytes resulting in fibrosis. TGFβ1 levels were increased significantly following BDL as seen by western blot and Real
time PCR analysis. Treatment with TFO showed a significant reduction in the TGF-β1

90

levels. There was also a decrease in the α-SMA levels in the TFO treated group compared
to the non-treated BDL group suggesting that the inhibition of collagen can also lead to
down regulation of α-SMA levels.
The hydroxyproline levels in TFO treated group was very less compared to the BDL
group. This is in line with our previous studies suggesting the inhibition of transcription
of Type I collagen. The serum TNF-α levels were elevated following BDL, and was
higher than that in the TFO treated group. TNF-α is a mediator of hepatotoxicity and is
upregulated in several animal models of chronic and acute liver injury. Masson’s
trichrome staining revealed a significantly high staining for collagen in liver sections
obtained from BDL group which decreased after treatment with TFO. There was also
seen an increase in concentrations of ALT and AST levels following BDL. TFO
treatment showed a decrease in the concentrations of the ALT and AST levels indicating
the effectiveness of TFO in attenuating liver fibrosis.
TFO treatment inhibiting the transcription of Type I collagen helps in attenuating
fibrosis induced by BDL. It also further inhibits the EMT, thereby decreasing the
development of profibrogenic cells and inhibiting the accumulation of ECM. Although,
the mechanism of TFO inhibiting the EMT needs to be thoroughly investigated, this
study shows the beneficial effects of TFO and it can be a good candidate for treating
fibrotic disorders.
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